integrate report year end december n h significance corporate symbol symbolic representation otsuka group corporate philosophy corporate symbol adopt initial corporate motif represent sky large render grada tion otsuka blue small otsuka red represent focus energy otsuka wellspre tenet offset form poise balance otsuka spell open friendly typeface corporate symbol convey otsuka group energetic commitment human happiness good healththe challenge spirit innovative creative handed manufacturing begin year ago original otsuka company establish manufac otsuka group company create range product otsuka turer raw chemical material bittern famous salt pan naruto tokushima provide pioneer market new product pocari sweat prefecture japan founder busaburo otsuka bear say health drink provide unprecedented value oral anticancer agent antipsychotic busaburo far land average farmer time want start busi unique action mechanism equolcontaine food equelle promote ness aim make great stride turn thought industry spirit women health beauty hand day backdrop steady business diversification includ continue provide new product solution contribute health ing entry iv solution business nationwide global expansion people world innovative creative manufacturing decision challenge spirit otsuka boldly seek unknown satisfied status quo mean creative product service will not produce continue seek challenge free preconception secondgeneration president founder masahito otsuka busaburo otsuka otsuka holdings co ltd integrate report challenge otsukas thing end antituberculosis drug deltyba aquaretic adpkd treatment drug samscajinarcjynarque widely world grit bring market year difficult research development equelle support women health beauty develop year research soybean aim create new market take long time value longpopular oro namin c drink calorie mate recognize otsuka determination persistently challenge unknown field start resolve result end corporate culture nurture year hand approximately employee work country region world brand adpkd treatment multiple region outside japan brand adpkd treatment otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report ot suka originality contribute health total healthcare company base endure mission contribute health people worldwide otsuka advance pharmaceutical business diagnosis treat ment disease nutraceutical business help people maintain improve daytoday health strive establish altogether new market develop product ground sciencenot pharmaceutical nutraceutical include func tional food drink persistently infor matively communicate novel value product otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report integrate report begin fiscal edition otsuka holding combine annual report csr report single integrate report corporate philosophy bring financial information nonfinancial information hope deepen stakeholder understand group aim indispensable contributor people health worldwide produce report refer interna tional integrate reporting framework advocate international integrate reporting council iirc guidance collabo rative value creation develop japans ministry economy trade industry reporting period precaution forwardlooke statement fiscal january december integrate report summarize operate financial result otsuka holding information january include co ltd subsidiaries fiscal january december keep corporate philosophy otsuka mottos jissho actualization sozosei creativity include information select material event occur january scope reporting date publication report contain forwardlooke statement pertain otsuka group strive pursue achieve otsuka group support live people worldwide principle report cover otsuka holding co ltd subsidiary activity plan projection strategy prospect otsuka group company wide range innovative creative product include pharmaceutical functional beverage func datum restrict scope note report statement base current analysis belief light information available issue date report actual result differ risk tional food dedicate cultivate culture dynamic corporate climate reflect vision health reference guideline uncertainty affect otsuka group operation care company find way live harmony local community natural environment global gn rte r sn ta nio dn aa rdl sintegrate reporting framework iirc medical information perspective contribute affluent healthy life people iso integrate report unify brand product different brand environmental reporting guideline edition moe name different country region sake readability product guidance collaborative value creation meti etc available country available different brand name different indication different dosage strength note information pharmaceutical product include product development intend kind advertising promotion medical advice otsukas goal indispensable contributor c n e n people health worldwide otsuka group operate business goal indispensable contributor people health world wide fulfilling corporate philosophy activity operation encompass core business pharma ceutical business provide comprehensive health support diagnosis treatment disease nutraceutical business help people maintain improve daytoday health endeavor create message feature value creation unchanging value improve people health worldwide continue provide value society president section nutraceuticalsnutrition pharmaceutical message president access medicine growth trajectory review second mediumterm fight tuberculosis seek provide value management plan old disease new face business essence management outline mediumterm value creation model management plan financial highlight nonfinancial highlight sozosei resist urge copy pursue creativity otsuka capable deliver business strategy foundation datum section jissho seifactualization section value creation achievement completion actualization discovery truth research development otsuka group csr main data pharmaceutical business society management discussion analysis nutraceutical business environment consolidate financial result fiscal ryukan godo process discover consumer product business governance core substance businesse director audit supervisory board consolidate financial statement sweat recognize hard work member group structure overview main way practice operating company global network c orporate informationshareholder information otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report message president message president business model goal new innovation unique business model tatsuo higuchi president representative director ceo otsuka holdings co ltd business model healthcare environment characterize expand medical cost age society include medication cost chronic illnesses dementia cancer publichealth need address treatmentresistant emerge infectious disease emergence new lifechanging health technology partly response development penetration generic drug reform drug pricing system proceed increase speed mean people grow interested daily disease prevention measure base lifestyle modification area nutrition exercise rest base mission contribute health people worldwide otsuka group activity base pillar pharmaceutical business extend diagnosis treatment disease nutraceutical business help people maintain improve daytoday health business model base belief healthcare wholebody phenomenon fully actualized continue provide innovative product service meet demand time include lifestyle evolution note seek synergy collaboration multiple group company drive innovation creation new market believe distinctive approach position tangible contribution resolution healthrelate social challenge create new value pharmaceutical nutraceutical global total healthcare business business diagnosis maintain treatment disease improve daytoday company health embracing challenge base endure mission innovation derive synergies core brand nutraceutical businesspocari sweat calorie matewere bear perspective technology knowhow gain clinical nutrition business base motto mission otsuka people create new product well health world engage simultaneously expand medical device business lever wide otsuka group work hard create innovative product order meet universal age otsukas strength pharmaceutical exploit new path total healthcare diverse business portfolio food beverage pharmaceutical address wholebody health aspiration people world stay healthy end constantly ask pharmaceutical business group company foster flexible groupwide strate practice otsuka achieve contribute society core gy decision make nutraceutical business group company share information tenet management help realize sustainable continue global committee global health issue consumer expectation business generate firstandonly innova nutraceutical business embrace challenge base mission sweep current moment tion unique approach seek leverage otsukas soft hard asset group company soft asset include corporate culture philosophy deep ingrain knowledge base nearly year history commit workforce pas sionate aim hard asset include advanced technology infrastructure span ning globe otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report message president selfactualization discovery truth achievement completion case indispensable contributor people health worldwide pharmaceutical jissho actualization occur drug approve reach business environment undergo significant change impact patient sozosei term akihiko otsuka thirdgeneration leader group change include advance basic science influence diseasetreatment system profusion company base determination pursue otsuka achieve imita information datum broad societal evolution people expectation tion underscore policy create innovative product defy exist preconception ryukan godo calligraphic work otsuka lifestyle social circumstance founder busaburo otsuka shift context thing otsuka achieve example digital technology datum information open opportunity deep insight area disease treatment affect individual patient consumer balance consider realize ryukan godo jissho sozosei ation product flavor healthiness obligate use insight responsi policy use hand sweat find essence solution imita bly behalf society company protect individual privacy tionto develop launch secure product market deploy otsukas uncommon management style principle continue deliver example samscajinarcjynarque revolutionary aquaretic agent take year sustainable growth help address healthcare challenge quest indi develop resulted research begin physician request want diuretic pensable contributor people health worldwide excrete water year hard work samscajinarcjynarque avail able patient world treatment autosomal dominant polycystic kidney disease adpkd inherit disease therapeutic treatment monument engrave corporate nutraceutical area pocari sweat develop beverage easily replenish philosophy tokushima prefecture japan water electrolyte ion lose sweating launch japan otsuka value beverage break establish market preconception sell unusual bluecolore relatively light taste time take gain accep distinctive corporate culture cul tance consumer emphasize value new drink employee conduct sample session help consumer experience effect result meticulous effort tivate year firmly establish brand create completely new ion drink market japan outcomes mediumterm management plan nucleus corporate culture foundation otsuka group business corporate culture important princi overview overview second mediumterm second mediumterm ple culture ryukan godo commitment jissho actualization sozosei creativity management plan management plan ryukan godo term coin busaburo otsuka founder otsuka group p mean discover core substance truth matter hard work practice jissho main principle convey masahito otsuka secondgeneration leader diversify revenue structure achieve sustainable growth mediumterm management plan fiscal maximize value antipsychotic agent abilify second mediumterm management plan fiscal abilify patent expire determined important priority diversification revenue structure plan period strength ene broaden business revenue pillar build foundation support group sustainable growth second mediumterm management plan outcomes issues pharmaceutical business seek reinforce therapeutic franchise enjoy steady growth new global product include abilify maintena rexulti samscajinarcjynarque result rebuild robust revenue foundation signifi not progress maximization investment cash flow grow core otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report message president business nutraceutical business reform consistently deliver oper human resource seek otsuka ate profit margin percent high thank effort achieve objective people embrace challenge rejuvenate product portfolio move business sustainable growth hand encounter number hurdle business environ determination ment japan challenge dramatic reform drug pricing system steppedup measure promote use generic drug addition create entirely new drug offering area therapeutic precedent market jynarque abilify mycite firstever digital medicine development commercialization pro cesse unprecedented product light challenge respect diversity believe key priority maximize corporate value anticipate major change take otsuka group consist company employee worldwide place business environment half overseas employee aim company diverse employ ee excel regardless nationality difference require corporate culture employee feel fulfillment find new value mutual acknowledgment active acceptance different background mindset tradition occasional clash outline outline mediumterm management plan differ perspective otsuka embrace diversity concept mediumterm mediumterm management plan period advance take hold japan actively utilize diversity human resource management plan grow global market total healthcare company p focus maximization exist business value expansion global prod uct abilify maintena rexulti samscajinarcjynarque lonsurf form strong basis second mediumterm management plan encourage challenge addition create new value challenge new modality category otsuka embed culture base take challengesdoe com geography contingent regulatory approval latestage candidate new therapeutic panie choose fact try type chal area revenue driver avanir pharmaceutical avp development lenge need use invigorate organization start scratch need mental health disorder vadadustat development anemia secondary chronic kidney consider proceed form hypothesis action start disease collaboration akebia therapeutic nutraceutical business aim work sticky resolve end believe approach lead subsequent challenge grow nature line lead supplement sector vitamin product tailor growth need individual consumer daiya food portfolio delicious plantbase food willing embrace challenge otsuka provide culture active support expand product line distribution channel appeal millennial consumer responsibility people give responsibility feel commit investment future growth balance discipline focus profit margin responsible accumulation experience result personal threfore shareholder return development mediumterm management plan period time sustainable growth seed plant second mediumterm management plan period sprout large tree develop executive lead company ceo personal area focus development executive human resource lead company future business management equate people work aspiration people not grow otsuka celebrate th anniversary order grow creatively indispensable contributor sustainably year believe cultivation human resource especially people health worldwide nextgeneration leadership extremely importanton par make medium longterm capital investment reason otsuka holding open otsuka global academy con nth duct executive human resource development program base swiftly identify mediumterm management foster future leader turn support development employee mediumterm plan specifically program otsuka group employeesthe senior leadership pro second management gram middle leadership program global leadership program uppermid mediumterm plan mediumterm management dle level manager otsuka group company world employee mana pg lae nment plan participate date program convey late managerial knowledge skill emphasize continuity relevance business approach practice successfully found include managerial leadership style successive generation otsuka leader perceive business case study success failure otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report message president define csr broad sense integrate business not pro mote sustainability business pharmaceutical nutraceuti cal product create produce help people maintain improve health realize well life aim simultaneously achieve sustainable growth healthy sustainable society enable access product deltyba mention constantly pursue activi tie aim contribute way otsuka november otsuka holding signatory united nations global com pact signatory express support global compact ideal time helping achieve sustainable development goal sdgs adopt united nations summit way reaffirm otsuka group commitment work society order achieve sustainable development executive human resource development program risk preparedness discussion center type qualification human resource require leadership prepare risk important sustainable corporate growth healthcare company effective decisionmake method involve people live product quality essential business work continuously academy place participant feel learn directly discus maintain improve quality value chain mind otsuka pharma sion hope participant complete program understanding otsukas true ceutical quality assurance department independent production department nature sense ownership reflect work want participant head executive directorlevel leader convey feel learn academy fellow employee hold global product quality meeting participant include man time young employee otsuka ask ager head quality control meet discuss quality issue futureoriente initiative value company result learn thing predecessor come addition conduct internal audits plant regularly strive ensure reliability find answer teacher training program pass finding datum specifically introduce computer system prevent important document employee age struggle answer question datum relate quality production falsify spend month human resource development include preparation maintain improve compliancerelate awareness employee time travel thing learn think engage world produce universal training material conform otsuka group global young colleague discussion business base multiple perspective code business ethic global anticorruption policy employee attend training want continue teach learn hand hand lead company annually compliance violation profound impact survival company reason promote continuous global measure ensure employee engage work base high ethical standard consider otsukas big risk forget root deep stead fast root tree grow large daily activity csr activity integrate business forget learn important principle corporate culture ryukan godo commitment sweat recognize way jissho actualization sozosei creativity pursue contribution csr p otsuka help realize sustainable society adhere corporate philosophy help realize sustainable society deltyba world new antituberculosis drug year coun try worldwide today address drugresistant tuberculosis public health problem especially area inadequate health system otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report message president review active rd investment core therapeutic area second mediumterm management plan strengthen product franchise core therapeutic area sustainable growth plan continue active investment rd working strengthen drug discovery capability maximize value new product lineup drive growth focus core therapeutic area time invest outside project establish diversified revenue structure achieve sus bring synergy exist knowhow intellectual asset enhance development pipeline combine effort move rd activity forward ensure future sustainable growth contribute social issue tainable growth psychiatry neurology oncology cardiovascular renal second mediumterm management plan hereinafter refer plan fiscal final fullscale entry neurologic area establish groupwide drug discovery develop nextgeneration core year set high priority diversify group revenue structure achieve sustainable growth strengthen psychiatric area platform introduce new therapeu area tic technology pharmaceutical business pursue strengthen core therapeutic franchise nutraceutical fullscale entry area neurol license vadadustat drug ogy acquisition avanir strengthen inhouse drug discov development renal anemia business hereinafter refer nc business pursue business transformation structural pharmaceutical ery capabilitie akebia therapeutic reform achieve growth final year final year second h afac fvq ee cu ti c ri peti bao e f c nl un nic ta al p pe ev de l mop rke en f oca r p pa sb euili dti oe bs uth lba r c p pot h hr l ae la r rn mbg rh c cae e etn u uioe tn d c c si l lyn ss te ner dmg r co se tu n ep x e rr eu dg ni tc ao ihve thnc rdq u uki gir de hnd ae cyn q dt ui ib iseo itad oy e n p r oela flat f vto e isr dm ep rt rpe ac eh linn eo logy establish diversify mediumterm management plan mediumterm management plan agc iq tau ti ir oe nd aa p soro cd iau tect u wn d r lze hve el io mp em rsent avp rigcq hu tsi r ie nd se iav e fl oo rp ne dt ea nn od m nea r rk ee ct ei pn tg r e bx sia nn ed sse global investment medical device expansion cns business merger antagonist arcus biosciences acquire ultrasound renal denerva revenue structure fy fy otsukas assets psychiatric area business entry genetically modify cell therapy tion treatment device technology license fremanezumab japan platform acquisition recor prophylactic migraine drug candidate sign joint development exclu medical facing end exclusive sale period teva pharmaceutical industry thiv ee gsa el ne es tc ho en rt ar pac yt w ruit gh nk ya r ea obi acquire arterial stent business founda consumer product world digital medicine system sitcr cd car japan tion cuttingedge product abilify group main product business abilify mycite approve acquisition veryan medical business central neurological obtain exclusive development pursue diversify revenue structure exclude abilify ac dq hu dir e td h en rae pu ero uv tia cn dc ee v en lod p mb et nai tn de rd u g woan rlu df wa ic dt eu r fi rg man md g r k ce ati rn g r cig elh l ts achieve sustainable growth invest abilify centanafadine therapy osaka university nutraceutical aggressively growth make strategic business oncology alliance business area grow steadily cardiovascular lead new product line result renal nc business achieve priority diversify sale pharmaceutical earning structure improve profitability revenue bn revenue bn nc business pursue fundamental reform operate profit nutraceutical business jgaap ifrs business practice review business asset revenue revenue external customer second mediumterm implementation strategy accelerate management plan billion operating profit pharmaceutical business global expansion develop new product operate profit margin review business practice base value chain focus development ingenious new maximize product value product contribute extension healthy life expec tancy improvement product value utilize scientific achieve target sale revenue new product line evidence experience cultivate pharmaceutical promotional activity help customer recognize building foundation continue drive group regrowth health benefit product accelerate global expansion core brand include pocari sweat plan categorize antipsychotic agent revenue new product global expansion result oronamin c drink enter plantbase longacte injectable abilify maintena antipsychotic business acquisition daiya foods agent rexulti vreceptor antagonist samscajinarc bn jgaap ifrs jynarque global product anticancer b lli n c h e e n r te e f f ort hth ee dg oro f u scp h h ea ds u lec h ai ne dv e ed ta b lo isp er da bg u sina erg ssin rf u co tv ue rr e trau ne ito io n c ah l pn eg rie din c oh e rc ino gn hl eid nat ine ed mfis oc na tl hy se frr f mis c aa pl r il e dn ed ce ed ec b e r agent lonsurf nextgeneration product new necessary constantly maintain level operate margin drug launch japan domestic new prod uct consider growth driver accelerate global expansion plan period actively invest management resource approval addition new indication expansion sale area early maximization asia north america europe product value pocari sweat plantbase food nutrition sant result total revenue new product line establish subsidiary thailand enter plantbase food sector acquire daiya food strengthen fiscal increase billion yen rd p nhi alip mpi ne c rtr ie nn kg sale nutritional supplement p foro r fu rec eti frn mys tem initial target billion yen successfully estab global product nextgeneration product new drug japan start local production sale enter natural food channel acquisition foodstate product indonesia lishe foundation strongly drive group change consolidated fiscal year fiscal end december soyjoy equelle transitional period cover month april december start local production indonesia start roll market regrowth plan otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report message president outline mediumterm management plan business strategy maximize exist business value new value creation otsuka enhance strategic initiative designating follow product brand growth driver global prod uct pharmaceuticals abilify maintena rexulti samscajinarcjynarque lonsurf major brand pocari sweat advance global market unique nature nutrition sant nurture brand nc business daiya food equelle bodymaint additionally otsuka launch nurture new product line drive sustainable growth pharmaceutical nc business total healthcare company growth driver revenue forecast pharma new product line bn fiveyear growth phase product line schedule launch bn corporate philosophy otsukapeople create new product well health worldwide pharma global product practice management spirit ryukangodo commitment jissho actualization sozosei cre abilify maintena samscajinarcjynarque ativity follow philosophy spirit otsuka create new value engage rexulti lonsurf approx unique business identify true insight need world create new concept product effec bn e tively combine science technology mix exist business spinout pioneer bn nc nurture brand untouched niche area define mediumterm management plan fiveyear period growth daiya food bodymaint establish unique total healthcare company global market focus core equelle business pharmaceutical nutraceutical go maximize value exist business create e new value practice business management corporate wide awareness capital cost bn nc major brand pocari sweat nutrition sant nature e e e e e e e e e e performance target rd mtm plan th mtm plan business profit cagr growth strategy help organic growth exist business pharma key performance target billion maximize value exist business ceutical nc business plan sale revenue e e cagr pharmaceutical challenge new frontier otsuka reach billion yen fiscal final year plan ae business generate innovation creative diverse research platform revenue increase billion yen business prof rd expense reach billion yen b ru din ee xs ps ep nro sefi st nutraceutical create new concept keep eye change environment challenge new category new area record high target business profit fiscal ratiorevenue business continuous high profit structure set billion yen cagr addition rd expense continue actively invest research development business profit sustainable growth ratiorevenue financial policy roe note exchange rate assumption euro business management corporatewide awareness include performance growth strategic investment etc business profit revenue cog sga share profit associate rd expense capital cost revenue plan organic growth e otsuka go implement business management awareness capital cost reflect business bn bn corporatewide awareness capital costs midterm risk period promote group performance assessment take account capital cost business strategic investing otsuka work bn improve return invest capital roic medium roic improvement optimal financing midlong term basis longterm time horizon monitor roic actively return business capital cost bn invest new value creation maximize pharmaceutical business investment financial policy bn business gi rn wfin tha n inc vin eg st mc eti nv tit si e ws h ilet cu ok na iw deill r ne gc u thre e n oe pc te imss aa lr c af pu tad ls strat ogi ie cs management stp ruti cm tua rl e capital co vrp ao lur eate maximize exist business value structure active investment effort aim maximize corporate create new value nc business bn value bn consumer business presentation material mediumterm management plan available otsuka holding website httpswwwotsukacomenirlibrarypresentationhtml e e e e e revenue external customer otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report feature access medicine access medicine sdgs target end epidemic hivaid tuberculosis malaria feature neglect tropical disease combat hepatitis water borne infection commu nicable disease fight tuberculosis number individual infect annual death mycobacterium tuberculosis tuberculosis old disease new face global public health improve thank deltyba tuberculosis drug approx billion approx million united nations un millennium development goal mdgs adopt mdgs goal combat hiv aid great progress un announce sustainable development goal sdgs inherit ideal tuberculosis spread limitation conventional medici mdgs embark new initiative achieve goal worldwide nal treatment deploy tuberculosis drug deltyba otsuka group seek ing eliminate tuberculosis list target sdgs tuberculosis spread worldwide tuberculosis currently multiple drug treat tuberculosis contribute improvement global public health world infectious disease malaria drug administer bacteria resistant hivaid approximately million people develop tuberculosis treatment usually involve administer drug year million die making lead case drugsensitive tuberculosis successfully ing cause death infectious disease tuber treat firstline drug proper case management culosis highly contagious billion people say recent year emergence resistance tubercu infect mycobacterium tuberculosis mtb bacteria losis drug widespread discontinuation medica global population billion tion reason irregular dose effect mtb develop active tuberculosis disease give rise bacteria resistant drug stubborn bacterium patient contract take multidrugresistant tuberculosis disease continue take multiple medication combi mdrtb bacteria resistant rifampicin nation month drugresistant isoniazid potent firstline therapeutic agent strain tb prevalent low middleincome coun extensively drugresistant tuberculosis xdrtb resistant try lowresource setting tuberculosis require great number drug represent major global longterm treatment represent major economic challenge challenge campaign control disease highburden country global tuberculosis report global distribution tuberculosis patient tuberculosis airborne infectious disease tuberculosis mycobacteria enter body datum multiply mainly lung result symptom cough production applicable sputum case infection cause breathing difficulty affect organ potentially result death highly contagious disease take hold case develop year reference global tuberculosis report infection weakening immune system otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report feature access medicine deltyba improve global health new external drug year collaboration birth deltyba expand access tuberculosis drug deltyba supply route st p bgdf lowincome country collabora otsuka wholly own tion stop tb partnership subsidiary otsuka pharmaceutical deltyba receive approval treatment mdrtb drug accord report publish treatment global drug facility stoptbgdf completely different mechanism action com action group tag patient advocacy group combat otsuka order pare previous therapeutic agent effective hivaid tuberculosis otsuka pharmaceutical larg deltyba new tuberculosis drug approve novel program gdf tuberculosis bacteria resistant exist e private funder tb research development year meaningless drug acce product ing drug expect play role therapeutic sible patient say tuberculosis patient gmbh drug mdrtb develop country africa asia region delivery deltyba include model list essential funder tb research otsuka group business base reason edi dci en le ts bli ast io f p nr eio ori ft th er u ng es w en n tuy bc eo ru cn ut lory drug approve orf gu nd izi tg ion sector total usd perc fe un not inf gtotal w fae c ib lite yg sn w po tbrk gin dg fw ah n oh g nto izp tt ib np dr et dn ie cr th ei dp og elo xb pa al n dir nu gg pharo mt asu cek ua ical gdfs supply agency order program world year mdrtb currently nih public access qualityassure tuberculosis drug diagnostic delivery gain prominent attention tuberculosis research regard bill melinda gates agent ensure sustainable procurement drug philanthropic foundation fashion pharmaceutical industry recently develop country stoptbgdf supply deltyba government agency relevant ngo country earmark usaid public rifampicin discover country patient cur support global fund unitaid multilateral thought tuberculosis treatable disease rently take drug receive medicine procure delivery researcher research institute otsuka private stoptbgdf highlight organization excellent contribu pharmaceutical world stop development otsuka company tion expand access medical institutionpatient uk dfid public continue research base belief tuberculosis found stop tb partnership mission serve person vulnera company x private ble tuberculosis ensure highquality diagnosis treatment care available global health problem continue need stoptbgdf large global provider qualityassure antituberculo european commission public research deltyba create sis medicine diagnostic laboratory supply public sector provide cdc public technical assistance tb program support wide use innovative tool year research activity otsuka pharma ceutical remain actively engage rd new tuberculosis edctp public topic cooperation japa deltyba research history nese government rifampicin discover standard treatment tuberculosis deltyba cooperate receive otsuka pharmaceutical commence drug discovery research work infectious disease key theme support japanese govern fullscale research tuberculosis drug started ment way include clinical trial start opc later deltyba treatment tuberculosis support access initiative deltyba approve launch europe japan therapeutic drug multidrugresistant tuberculosis mdrtb sea share educational infor deltyba add model list essential medicine mation international conference item economic cooperation plan united nations general assembly highlevel meeting agree japanese russian leader improve tuberculosis hold new york city september agreement conclude stop tb partnership global drug facility gdf event medical care promote healthy life span katsunobu kato minister health labour eastern economic forum hold vladivostok september welfare give speech develop treatment license agreement execute rpharm russia manufacture commercialization deltyba russian federation japans prime minister shinzo abe speech multidrugresistant tuberculosis japan contribute surround country mutual cooperation aim get swift approval eradication disease worldwide deltyba russia speech say fight time adopt political declaration eliminate licensing agreement execute mylan india expand deltyba approval commercialization activity highburden tuberculosis japan russia join hand tuberculosis country otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report deltyba improve global health value eessttaabblliisshhiinngg aa ssuuppppllyy nneettwwoorrkk wwhhiicchh creation wwiillll ssaavvee ppaattiieennttss aarroouunndd tthhee wwoorrlldd section expand access patient n terview worldwide growth trajectory numerous collaboration form combat tubercu indispensable company global health losis disease threaten global health eeking provide value rd institute conduct unique research united nations national government business imitate company pursue provide active support addition aforementione otsuka deltyba embodiment v alue creation model cooperation gdf otsuka pharmaceutical contribute effort tuberculosis global health health people world collaborative financial highlight problem approach problemthe belief initiative stakeholder include partici somebody confront disease nonfinancial highlight pation global health innovative technology fund ghit remain unchanged japanese publicprivate partnership establish address infec year otsuka initiate research base tious disease worldwide cooperation program corporate philosophy otsukapeople create new spearhead mdecin san frontiresdoctor bor product well health worldwide con ders msf obtain support bill tinue work external stakeholder benefit melinda gates foundation development new tubercu global health sense speed commitment losis treatment method form alliance activity continue address global company strength public health issue solve globally pro operation area business opera cess believe fulfill aim tion mylan indiasouth africa rpharm russia indispensable contributor people health worldwide march launch new delamanid clinical access program dcap cooperation south african government aim national program patient mdrtb swift access deltyba regulatory approval initiative otsuka pharmaceutical working establish sustainable drug delivery system affordable keiso yamasaki price patient world need deltyba otsuka pharmaceutical co ltd treat regardless socioeconomic status income level global project leader june country expand use tb project deltyba base multifaceted approach column nextgeneration tuberculosis drug candidate opc hiz tower otsuka pharmaceutical conduct research tuberculosis drug follow deltyba late development compound building picture call opc undergo initial trial south africa confirm safety efficacy tokushima research institute name opc kill tuberculosis bacteria mechanism inhibits activity enzyme essen drug lay foundation otsuka group pharmaceutical business tial synthesize mycobacterium tuberculosis cell wall mechanism action differ completely ceramic mural wall design exist antituberculosis drug include deltyba expect effective treatment taro okamoto call inochi odoru strain tb develop drug receive support bill melinda gates dance life name notable tokushima writer activist jakucho foundation cite elimination tuberculosis worldwide priority continue setouchi research center otsuka engage tb rd aim establish innovative treatment method pharmaceutical situate nearby otsuka holdings co ltd integrate report value creation section growth trajectory chemical raw material pharmaceutical beverage food otsuka group found chemical raw material manufacturer build iv solution business spur group growth continue diversify operation achieve steady growth bring market series original product oronine h ointment oronamin c drink bon curry pocari sweat calorie mate pharmaceutical antipsychotic agent abilify drug novel mechanism action samsca world oral aquaretic drug foundation phase growth phase expansion phase start business naruto numerous unique product open new market diversify seek global growth total healthcare company tokushima prefecture japan business pharmaceutical business antipsychotic agent abilifywhich go sale otsuka group start period group leverage technology knowhow cultivate available prescription roughly country region greatly manufacturer chemical raw materi expansion iv solution clinical nutrition product business successively spawn accelerate otsuka group global expansion today therapeutic drug pro al production magnesium unique core brandsthe ion supply drink pocari sweat balance nutritional food calorie duce inhouse drug discovery program help treat disease worldwide carbonate derive bittern mate world commercial retort pouch food product bon curry start pharmaceutical include longacte antipsychotic agent abilify maintena new antipsy residue remain salt pan inhouse pharmaceutical rd establish group business foundation deliver total chotic agent rexulti vreceptor antagonist samscajinarcjynarque anticancer salt production business healthcare solution twin business segment pharmaceutical nutraceutical agent lonsurf nutraceutical business group company address health issue steady progress supply broad need different corner world example pharmavite operate nutritional range pharmacopeia raw material supplement business mainly nutrition sant nutritional food company europe enter iv daiya food develop plantbase food north america solutions business expand nation wide launch intra venous drip solution world commercially available food balance nutritional food product retort pouch bon curry calorie mate launch lonsurf launch equelle international business development phase launch jinarc rexulti bbiilllliioonnss ooff yyeenn launch abilify maintena start aggressive global expansion quality vital factory packaging draw advanced technological knowhow cultivate japan start manufacture market put expand iv solution business overseas market cur consumer position otsuka group guide precept rently business company worldwide manufacturing selling launch samsca founder handwriting express commitment product commit local manufacturing aim maintain quality serve basis otsukas improve quality think contribute local community mainly manufacture today form fair product pricing employment creation begin market pocari sweat overseas product sell country region original iv solution year experience intravenous solution business launch abilify lead company forefront japan iv solution industry china otsuka pharmaceutical co ltd indonesian high school student enjoy otsuka japanese pharmaceutical ing pocari sweat company establish joint venture china launch ts establish otsuka seiyaku kogyobu launch pletaal establish pharmaceutical research launch calorie mate start iv solution business institute l u n che pocari sweat la mu un cc oh se td launched launch inhouse devel launch uft oronine h ointment oped pharmaceutical mikelan meptin launch oronamin c drink launch bon curry revenue trend nutraceutical consumer product pharmaceutical change consolidate fiscal year fiscal end december transitional period cover month april december otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report value creation section seek provide value business value aim provide total otsuka group contribute people health worldwide create innovative product core business pharmaceutical business aim address unmet medical need healthcare nutraceutical business seek fulfill yettobe imagine consumer need otsuka innovative product social challenge unmet medical need diagnosis treatment pharmaceutical social challenge business yettobe imagine need maintenance improvement daytoday health nutraceutical business otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report value creation section value creation model corporate philosophy otsukapeople create new product well health worldwide otsuka group create new value address universal social challenge business innovative prod uct aim provide total healthcare solution base diverse quintessential management principle ryukan godo sweat recognize way jissho actualization sozosei creativity repeat business underlie capital ing value creation process aim realize sustained development activity society sustain growth group total healthcare solution human capital number employee diversity inclusion innovative diversity p products financial capital total asset sozosei billion creativity creation social value manufacture capital jissho solve social challenge manufacture basis actualization total healthcare underlie input ryukan godo capital intellectual capital unmet medical need sweat recognize way solution aim rehabilitate patient suffer rd expense psychiatric neurological disease pharmaceutical business comprehensive patientoriente cancer treatment billion world therapeutic drug develop voice realworld clinical setting latephase development initiative eradicate tuberculosis project project project phase ii later stage p yettobe imagine need brand help people maintain improve health sciencebase product discovery raise people health awareness educational social relationship capital activity creation company outcome social value physical mental health employee development country region human resource establishment value chain aim realize sustain able society natural capital scope otsuka holding subsidiary environmentally friendly manufacturing affiliate company december otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report value creation section financial highlight change consolidate fiscal year fiscal end december transitional period cover month revenue rd expense pharmaceutical business billion revenue overseas sale billion rd expense pharmaceutical business rd expense ratio ratio pharmaceutical business yoy yoy billion billion revenue grow previous year mainly rd expense pharmaceutical business increase growth sale growth driver pharmaceutical previous year result active rd investment business global product abilify maintena maximize value inhouse develop product samscajinarcjynarque rexulti new product core therapeutic area psychiatry neurology oncology japan grow sale volume pocari sweat nutraceu cardiovascular renal system tical business contribute revenue growth revenue rd expense pharmaceutical business overseas sale ratio rd expense ratio pharmaceutical business jgaap ifrs plan jgaap ifrs plan operate profit total asset billion operating profit operating profit billion total asset ratio equity attributable margin owner company total asset yoy billion billion operating profit increase previous year ratio equity attributable owner company total spite increase rd expense onetime expense includ asset maintain high level promote ing impairment loss increase revenue pharmaceutical active investment enhance competitiveness business nutraceutical business absorb growth pursue operational efficiency operating profit total asset operate profit margin ratio equity attributable owner company total asset jgaap ifrs plan jgaap ifrs profit attributable owner company dividend share billion profit attributable owner company ratio profit attributable dividend share dividend payout owner company ratio yoy billion profit attributable owner company decrease otsuka group consider profit distribution shareholder previous year tax reform result important management issue basic policy large reduction defer tax liability previous year maintain stable continuous profit distribution securing exclude impact tax reform year result cash invest business growth prepare level previous year change business environment profit attributable owner company dividend share ratio profit attributable owner company dividend payout ratio jgaap ifrs plan jgaap ifrs plan otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report value creation section nonfinancial highlight number employee total co emission number number employee ratio employee outside thousand tonsco ton million total co emission japan target reduce co emission compare thousand tonsco otsuka group strive utilize diverse human resource japan otsuka group work reduce total co emission order adapt acceleration global business expan indonesia make efficient use energy use sion varied social need employee ratio outside cogeneration system renewable energy fiscal total india japan increase approximately north america co emission increase previous year increase production result acceleration south korea china global expansion europe total co emission co emission sale outside japan japan scope calculate consolidated subsidiary otsuka group compa scope otsuka holding subsidiary ny constitute co emission originate energy female manager ratio energy composition calorie conversion number female manager ratio otsuka group believe active involvement diverse human resource free open workplace environment invoke creativity turn lead sustainable corporate purchase electric power growth accordingly actively promote diversity include natural gas active participation female employee heavy oil etc otsuka pharmaceutical purchase steam coal etc otsuka pharmaceutical factory renewable energy taiho pharmaceutical scope calculate consolidated subsidiary otsuka group compa otsuka chemical number female manager female manager ratio ny constitute co emission originate energy otsuka warehouse scope company otsuka pharmaceutical otsuka pharmaceutical factory taiho pharma otsuka food ceutical otsuka chemical otsuka warehouse otsuka food number employee acquire childcare leave ghg emission value chain fiscal number number employee acquire childcare leave ghg emission emission scope category thousand tonsco otsuka group support employee achieve balance scope otsuka group assess environmental impact category b oe pt ew ne ine gn oc fh til hd rc ea er e w rd kp w lao cr ek n uh rr eu ryg fh cm ile ita ies su r te hs e n hc olu ldd ii nn gg oth f e e pm f r ooi ds urio c tn ss l df rom use eh ne v iv roa nlu ec nh ta ai ln mfo pr ait cs sf v ine ada djo itr io c ea mni ie ss ioin n j sa dp ua en tw ch rl par og te seminar achieve balance childcare work thousand tonsco scope activity scope calculate emission stem enhancement relate system activity supplier customer party scope continue effort calculate greenhouse category emission purchase gas ghg emission aim reduce co good service number emission value chain female male female scope company otsuka pharmaceutical otsuka pharmaceutical factory taiho pharma company otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical male ceutical otsuka chemical otsuka warehouse otsuka food otsuka chemical otsuka food otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report nonfinancial highlight water usage water use efficiency thousand thousand million water usage business target improve water use efficiency thousand compare strategy assess state water risk water section manufacture site world work achieve communitybased management effective use water resource order achieve sustainable society r esearch development outside japan japan rd activity scope calculate consolidated subsidiary otsuka group compa pharmaceutical business ny constitute co emission originate energy c ore product development p roject phase ii later resource recycling rate final disposal stage pharmaceutical business ton resource recycling rate social challengesstrength overview verview therapeutic otsuka group company japan promote area recycle reuse resource achieve recy ake challenge cling rate zero emission base internal standard address unmet medical recycling rate high fiscal need continue strive zero emission undertake nutraceutical business rs reduce reuse recycle social challengesstrength final disposal resource recycling rate overview scope major consolidated subsidiary japan global expansion rd framework c onsumer product business business th research center tokushima research institute picture otsuka group drug discovery center building house pharmacology synthesis department provide space researcher different discipline freely exchange information engage discussion otsuka holdings co ltd integrate report business strategy section research development rd activitiespharmaceutical business power aggressive rd investment aim contribute unmet medical need create inno proprietary drug discovery business model pharmav aa cen uir ticals visterra inc vative product generate new strength innovation group cooperation rd policy pharo mt asu cek ua tical factory astex pharmaceutical drive corporate philosophy otsukapeople create n toe w ac hp ir eo vd eu hct ig hfo lyr ib ne not ote var th ve ea l dth ru w g dr il sd cw ovid ee ry oth fe ss ou lk ua iog nro su fp ra ims rd expense inhouse drug discovery pharo mt asu cek ua tical pharmta ai ch eo utical unmet medical need goal mind engage multi billion lateral rd activity addition collaboration group company boast ing expertise numerous field work bolster otsuka group build solid foundation continue inhouse drug discovery platform include human resource devel drive innovation ahead time drug opment access innovative technology idea discovery research center otsuka pharmaceutical involve research support networkbuilde university rd strength area psychiatry neurology rd expense latephase development research institute bioventure possess leadingedge ratio project taiho pharmaceutical possess drug discovery research technology drug discovery seed technology platform focus oncology otsuka ratio inhouse drug discovery project latephase development project pharmaceutical factory lead company intravenous rd expense pharmaceutical business solution welcome group astex phar phase ii later stage development december maceutical pioneer fragmentbase drug discovery avanir pharmaceutical boast strength develop ment field neurological disease visterra inc rd basis company possess unique antibody platform technology china tsuka pharmaceutical development mutually share cuttingedge proprietary technology inherent tsuka shanghai research institute commercialization inc basic research tsuka beijing research institute astex pharmaceuticals viewpoint strong desire challenge difficulttotreat clinical development aiho pharmaceutical beijing co ltd clinical development disease continue rd level vanir pharmaceuticals inc south korea aiho oncology inc generate new strength innovation k orea otsuka pharmaceutical co ltd visterra inc singapore aiho pharma singapore pte ltd topic europe hierotope platform visterras proprietary antibody platform technology japan visterra possess proprietary antibody platform technology hierotope platform enable design antibody drug asia tokushima otsuka pharmaceutical target identify epitope think essential pro epartment drug discovery strategy tein function simulate computer bind epi epartment medical innovation shiga epartment cns research tope substructure countless antibodie hierotope epartment renal cardiovascular otsuka pharmaceutical research fujii memorial research institute refer region comprise robust threedimensional edicinal chemistry research laboratory hyogo structure amino acid believe play critical role epartment lead discovery research otsuka pharmaceutical okushima research institute ako research institute structure function activity protein combina uk astex pharmaceuticals f iarm gnu ola st ti io c n r ve iss ie oa nr c rh ds dit eu pte artment ibaraki tion computational experimental method technol drug discovery preclinical taiho pharmaceutical taiho pharmaceutical ogy design engineer antibodie strongly bind development discovery preclinical research division tsukuba area tsuka europe development ti os kco uv sher imy ad p ar eclinical research division tokyo hierotope unlike traditional approach completely novel commercialization ltd taiho pharma europe ltd otsuka pharmaceutical factory otsuka pharmaceutical technology enable design development antibodie n aruto research institute research diagnostic division rd department disease drug discovery target hitherto consider diffi germany development center headquarters clinical development otsuka novel product gmbh technical center otsuka pharmaceutical factory cult aim provide new therapeutic drug disease research development center clinical development unmet medical need remain department taiho pharmaceutical clinical development division osaka otsuka pharmaceutical headquarters clinical development otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section research development core product development ta trial ongoing drug candidate treat gastroin psychiatry neurology ta potential exhibit antitumor effect inhibit testinal stromal tumor gist rare form cancer e heat shock protein hsp destabilizing reduce japan gist malignant type tumor occur wall brexpiprazole track designation food drug administration fda multiple protein involve cancer growth survival hsp gastrointestinal tract patient experience brexpiprazole new antipsychotic agent novel mecha clinical trial avp ongoing psychiatric know particularly important survival mainte recurrence metastasis incidence rate japan nism action know serotonindopamine activity modulator neurological disorder unmet medical need nance cancer cell express highly cancer cell people sdam sell brand rexulti adjunc exist patient negative symptom schizophrenia tumor tissue exist highly activate state phase iii tive therapy major depressive disorder schizophre traumatic brain injury intermittent explosive disorder cardiovascular renal nia treatment japan europe centanafadine schizophrenia treatment clinical trial currently underway centanafadine triple reuptake inhibitor action mechanism utilize property agent order provide effective modulate norepinephrine serotonin dopamine vadadustat ultrasound renal denervation treatment device method treatment unmet field agitation reuptake currently undergo phase iii trial vadadustat oral therapeutic drug currently subject phase renal denervation system new treatment method associate dementia alzheimer type posttrau candidate attention deficit hyperactivity disorder adhd iii trial candidate treatment anemia associate potential effectively low blood pressure patient matic stress disorder ptsd adult adhd developmental disorder characterize diffi chronic kidney disease nondialysis dialysis patient hypertension exist hypotensive drug unable estimate approximately million people culty pay attention easily distract forgetful excessive work stabilize modulate hypoxiainducible factor technology downregulate hyperactivity renal g country suffer alzheimer patient activity impulsiveness fidgeting unable sit hif transcription factor activate erythropoietin sympathetic nerve catheterbase system percuta say exhibit form behavioral disorder estimate million potential adhd inhibit hif prolyl hydroxylase hifph enzyme break neously deliver ablation sympathetic nerve surround excessive motor activity verbal aggression physical aggression patient adult million child hif hif respond change oxygen concentration renal artery heat generate radio ultrasound symptom impact patientthey fundamental treatment method stimulant drug usually control gene expression involve production red blood wave renal denervation device develop place strain family member caregiver significantly prescribe pose problem effect cell hif act improve iron mobilization coordinat usbased otsuka group company recor medical utilizes mini affect quality life ptsd mental disorder develop central nervous system mental dependency drug resis e interdependent process boost red blood cell production mally invasive procedure blood vessel wall efficiently result exposure traumatic event experience severe tance abuse stimulant see problem ultimately oxygen delivery agreement achieve nerve ablation effect system characterize mental stress include earthquake natural disaster accordingly safe drug low risk abuse akebia therapeutic otsuka group acquire right deliver ablation concentrically renal sympathetic nerve fire accident violence criminal damage person suffer achieve comparable efficacy stimulant drug need joint development marketing vadadustat joint ultrasound energy artery wall keep cool ptsd afflict traumadriven fear anxiety development exclusive marketing europe exclusive circulate water artery trial currently underway attentiondeficithyperactivity disorder epidemiology mature market datum long time elapse number ptsd patient total pediatric adult adhd prevalent case dsmiv detail drdecision development marketing canada australia china investigate treatment hypertension resource llc right reserve reproduction distribution transmission publica g country estimate million tion prohibit country exclude central south america japan south korea examine potential treat fremanezumab refractory hypertension provide combination partial agonist activity serotonin hta dopamine country outside japan asia taiwan south korea singapore malaysia indonesia receptor antagonist activity serotonin hta receptor fremanezumab anticalcitonin generelate peptide cgrp etc mitsubishi tanabe pharma acquire license drug alzheimer disease epidemiology mature market datum total prevalent case ad drdecision resource llc right reserve reproduction distribution monoclonal antibody prevention migraine admin transmission publication prohibit istere monthly subcutaneous injection expect post traumatic stress disorder epidemiology mature market datum total expect completion phase iii trial key drug development end june month prevalent case detail dr decision resource llc right reserve prevent migraine selectively bind cgrp think reproduction distribution transmission publication prohibit key factor cause migraine inhibit cgrp psychiatry neurology avp bind receptor otsuka group conclude avp new compound deuteriummodifie dextro exclusive license agreement teva pharmaceutical industry fremanezumab fremanezumab centanafadine avp episodic migraine chronic migraine adhd adult agitation alzheimer dementia methorphan quinidine drug currently study development commercialization japan drug piiiiijapan sep piiiiijapan oct piiius piiiuseurope jun phase iii trial candidate moderatetosevere agitation currently undergo phase iii trial japan candidate avp brexpiprazole patient alzheimer dementia grant fast prevention episodic chronic migraine agitation alzheimer dementia agitation alzheimer dementia piiiuseurope oct piiiuseurope dec oncology cancer supportive care guadecitabine astx guadecitabine nextgeneration lowmolecularweight dna astx world oral dna methylation inhibitor com methylation inhibitor design allow active metab bination drug contain dna methylation inhibitor decit vadadustat vadadustat olite decitabine work long body effi abine metabolic enzyme cytidine deaminase inhibitor guadecitabine renal anemia dialysis renal anemia nondialysis relapsedrefractory aml piiiuseurope mar piiiuseurope aug ciently reach tissue bone marrow currently cedazuridine administration currently approve methyla piiiglobal sep phase iii trial indication relapsedrefractory acute tion inhibitor require patient visit hospital intrave tolvaptan opc guadecitabine siadh cardiac edema myeloid leukemia aml adult relapsedrefractory myelo nous injection orally administer astx relapsedrefractory mds piiijapan mar piiijapan jul piiiglobal jun dysplastic syndrome mds adult potential new treatment option alleviate cardiovascular renal burden mds patient meet primary endpoint phase iii trial treatment mds aim submit oncology cancer supportive care application approval end otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section research development project phase ii later stage march psychiatry neurology cardiovascular renal code generic brand country development status code generic brand country development status origin indication origin indication feature region phase ii phase iii file approve feature region phase ii phase iii file approve major depressive disorder jp eu cn opc tolvaptan otsuka syndrome inappropriate antidiuretic hormone samsca jp agitation associated dementia pharmaceutical secretion opc brexpiprazole otsuka alzheimer type jp eu v receptor antagonist rexulti pharmaceutical dopamine partial agonist bipolar disorder eu opc otsuka cardiac edema jp posttraumatic stress disorder eu v receptor antagonist pharmaceutical ep roc ni n n repinephrine dopamine reuptake inhibitor pht au rmka ceutical attention deficit hyperactivity disorder hik fb pr ly l h yd rv oxa yd laa se u in ht iba r akebia anemia associated chronic kidney disease eu tas taiho duchenne muscular dystrophy jp pgd synthase inhibitor pharmaceutical agitation associate dementia eu area alzheimer type avp nd du eat rr ei cu em ptom r ao nd tai gfi oe nd td se ex rotr nm ine nh nr op rh epa n e pq hu rii nn ei dine avanir negative symptom schizophrenia c feo atd ue sgeneric brand origin indication c ro eu gn iotr ny phase ii pe hv ae sl eo p iim ent f lt ea dtus approve reuptake inhibitorsigma receptor agonist traumatic brain injury opc delamanid intermittent explosive disorder deltyba otsuka multidrugresistant tuberculosis pharmaceutical eb centanafadine mycolic acid biosynthesis inhibitor neurovance attention deficit hyperactivity disorder norepinephrine dopamine serotonin reuptake inhibitor opc otsuka tuberculosis lu aa nalmefene dpre inhibitor pharmaceutical selincro lundbeck alcohol dependence jp opioid receptor antagonist opa otsuka atopic dermatitis jp tev fremanezumab pde inhibitor pharmaceutical teva migraine jp anticgrp antibody op otsuka clostridium difficile infection enteric infection jp new quinolone base antibacterial agent pharmaceutical oncology ta taiho stress urinary incontinence jp selective norepinephrine reuptake inhibitors pharmaceutical code generic brand country development status origin indication tas taiho feature region phase ii phase iii file approve multikinase inhibitor pharmaceutical idiopathic pulmonary fibrosis jp colorectal cancer cn tas trifluridine tipiracil taiho ta taiho rheumatoid arthritis jp lonsurf btk inhibitor pharmaceutical pharmaceutical interference function dna gastric cancer jp eu otsuka opf pharmaceutical peripheral parenteral nutrition solution jp ta tegafur gimeracil oteracil folinate taiho gastric cancer jp glucose electrolyte amino acid fat vitamin factory antimetabolite pharmaceutical tas taiho nonsmall cell lung cancer jp eu vis visterra influenza infection dutpase inhibitor pharmaceutical antihemagglutinin monoclonal antibody ta taiho multikinase inhibitor pharmaceutical prostate cancer jp tac meiji detrusor underactivity overactive bladder jp tas taiho gastrointestinal stromal tumor jp hsp inhibitor pharmaceutical ta taiho diagnostic cholangiocarcinoma jp eu fgfr inhibitor pharmaceutical tas taiho code generic brand country development status urothelial cancer jp origin indication peptide vaccine pharmaceutical feature region phase ii phase iii file approve taiho ta solid tumor eu ccac otsuka pharmaceutical measurement gastric acidity jp ccalcium carbonate breath test pharmaceutical ovarian cancer eu sgi guadecitabine odkcn otsuka astex acute myeloid leukemia jp eu diagnosis myelodysplastic syndrome cn dna methyltransferase inhibitor wt mrna rtpcr assay kit pharmaceutical myelodysplastic syndrome jp eu phase iiiii astx astex myelodysplastic syndrome phase iii dna methyltransferase inhibitor application takara bio inc astx astex solid tumor lymphoma iap inhibitor tbi takara bio synovial sarcoma jp nyeso sitcr gene therapy tbi canerpaturev takara bio melanom jp oncolytic virus tbi takara bio acute lymphoblastic leukemia jp cd car gene therapie pronetu fosnetupitant helsinn chemotherapyinduce nausea vomit jp nk receptor antagonist healthcare otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section pharmaceutical business social challengesstrengthsoverview provide total healthcare solution disease diagnosis treatment fiscal business overview mainstay product fiscal revenue profit boost high sale revenue new product japan overseas despite impact drug price revision japan low sale revenue longliste drug owe campaign promote use generic high rd cost associate progress latephase development product sale revenue come billion revenue ratio business performance fiscal yoy operating profit billion billion japan revenue operating profit abilify maintena rexulti north america revenue external customer antipsychotic longacte injectable antipsychotic generic aripiprazole origin otsuka pharmaceutical generic brexpiprazole origin otsuka pharmaceutical abilify maintena oncemonthly longacte injectable global alliance lundbeck novel atypical anti antipsychotic agent abilify discover otsuka pharmaceutical psychotic agent rexulti approve commercialize global alliance lundbeck drug adjunctive therapy major depressive disorder therapeutic treat schizophrenia adult patient launch drug schizophrenia japan europe approve social challenge otsukas strength europe japan currently sell therapeutic drug schizophrenia country sale revenue fiscal increase year drug high efficacy safety base novel mecha year billion mainly reflect great awareness nism action rate favorably physician patient line evolution life science number new corporate culture efficacy indication convenient formulation alike help boost fiscal sale revenue year drug discover year generate innovation increase prescription follow july addition mainte year billion disease lack effective treatment method disease otsuka group employee high regard nance treatment bipolar disorder adult approve indica exist treatment drug unsatisfactory address tion jissho actualization sozosei creativitythe dna ing desire people remain healthy universal corporate cultureand pursue innovation daily basis press issue question common practice rd departments pharmaceutical business consistently samscajinarcjynarque onsite operation embrace challenge solve issue standpoint patient medical professional alike roughly year mainly field psychiatry neurology oncol provide total healthcare ogy unmet need exist solution diagnosis treatment disease employ holistic approach people health conduct business wide array field include pharmaceutical clinical nutrition diagnostic agent medical device order vreceptor antagonist provide comprehensive healthcare solution diagnosis generic tolvaptan origin otsuka pharmaceutical approve use country treatment disease prescription drug oral aquaretic continued samscajinarcjynarque sell globally increase fiscal mainly reflect strong recommendation oral aquaretic drug brand samsca novel mechanism guideline japan treatment hepatic edema longheld knowledge core action excrete water body direct impact cardiac edema prescription treatment adpkd continue therapeutic area electrolyte excretion inhibit antidiuretic hormone vaso grow approve sale market europe sale pressin approve world therapeutic drug commence sale revenue rise commence rd field psychiatry neurology autosomal dominant polycystic kidney disease adpkd year year billion samsca grow sharp oncology continue step address brand samscajinarcjynarque year year billion jinarcjynarque unmet medical need spawn innovation form otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section pharmaceutical business overview therapeutic area psychiatry neurology oncology cancer supportive care field psychiatry neurology key area focus otsuka give disease cause expand business field oncology cancer supportive care aim provide discover difficulty involve drug discovery rd continue embrace patientoriente total care collaboration group company access cuttingedge challenge provide trailblaze solution aim rehabilitate patient society suffer knowledge innovative technology seek achieve high level drug discovery psychiatric neurological disorder aim provide systematic solution address challenge psychiatric spark new innovation meld proprietary technology neurological healthcare launch tegafurbase oral formulation futraful numerous compound owe proprietary fragmentbase japan taiho pharmaceutical pioneer market drug discovery addition dna methylation inhibitors psychiatric disorder schizophrenia bipolar major prescribe patient country region oral anticancer agent time use guadecitabine astx successor drug develop depressive disorder cause problem person social life career worldwide harness rd experience abilify draw uncommon half century anticancer drug research leverage knowledge dacogen generic decitabine study develop time childhood e feedback professional engage clinical practice company generate large body evidence treatment myelodysplastic syndrome acute myeloid late middle age concern grow develop rexulti new drug completely novel mecha contribute establishment cancer chemotherapy leukemia company currently promise drug increase alzheimer population worldwide continue nism action rexulti advance research japan primarily ts combination drug tegafur gimeracil undergo clinical trial age disease affect patient quality life address unmet major therapeutic need leave untreated world place strain family caregiver create burden widefor example schizophrenia major depressive disorder ptsd oteracil potassium standard treat cancer therapy system currently change rapidly healthcare economy illness satis agitation associate alzheimer disease ment unresectable advanced recurrent gastric cancer result advancement science technology devel factory treatment establish cause develop bring market longacte inject standard postoperative adjuvant chemotherapy gastric oping expand drug discovery platform technology mechanism fully understand make dis able like abilify maintena address issue medication cancer development commercialization harness respective strength group company covery new drug extremely difficult adherence trialing use abilify mycite world anticancer agent lonsurf subsequent establish step pace research development ment sale framework north america development collaboration alliance tieup corporation otsuka group start conduct research develop digital medicine system patient record tablet inge sale alliance francebase servi taiho pharmaceutical academia include open innovation initiative seek ment field psychiatry neurology tion develop digital therapeutic application treat continue challenge expand global pre promote access cuttingedge knowledge innovative tech day continue work tirelessly new drug development major depressive disorder continue focus unmet ence value creation nology achieve high level drug discovery goal contribute medical need discipline need patient aim provide systematic solution result research quarter century come address challenge psychiatric neurological healthcare astex pharmaceutical otsuka core product development p head development abilify world dopamine unique approach fuse different technology group contribute commercialization partial agonist evaluate highly clinical setting effi core product development p cacy safety base novel pharmacological action unmet medical need psychiatry neurology unmet need oncology schizophrenia gastric cancer schizophrenia psychiatric disorder thought emo gastric cancer fifth common type cancer world tion continue disorder appear adolescence common cause cancer death follow age maturity present symptom hallucina lung colorectal cancer estimate approximately tion delusion think disorder emotional flattening lack people die gastric cancer year japan motivation employment live society difficult common form cancer responsible roughly today advance science cause disease death annually surpass lung colon cancer fully elucidate need longterm remarkable progress recent year success therapy support aim return society ameliorate fully treat gastric cancer survival period dramatically symptom issue lack recognition disease increase past year say intensive chemotherapy reduce medication adherence effect lead treatment cancer progress relapse patient complication arise drug estimate million patient limit extend survival period alleviate symp misunderstanding prejudice psychiatric neurological collaboration shizuoka cancer center taiho pharmaceutical million japan million major country disorder exist society fully understand otsuka tom latestage treatment metastatic gastric cancer provide information help improve live cancer patient europe pharmaceutical confronting issue head carry numer challenge new treatment option certainly need offer support people experience cancer overcome ous activity aim educate people disease challenge face daily life family healthcare schizophrenia epidemiology mature market datum drdecision resource llc httpswwwotsukacojpenknowproject ferlay j soerjomataram dikshit r et al int j cancer e professional cancer survivor right reserve reproduction distribution transmission publication prohibit late cancer statistic cancer information service national cancer center reprint permission japan japanese otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section pharmaceutical business adpkd treatment samscajinarcjynarque take challenge address unmet medical need cardiovascular renal guide motto otsuka otsuka group continue develop pharmaceutical novel mechanism action efficacy disease samscajinarc jynarque offer lot hope new drug renal field treatment autosomal domi core therapeutic area addition psychiatry neurology oncology nant polycystic kidney disease adpkd condition hitherto know treatment inhouse develop pharmaceutical hypotensive aggressive growth investment illustrate vadadustat adpkd characteristic number patient country result drug approve japan drug mikelan launch continued contribute business alliance akebia therapeutics acquisition autosomal dominant polycystic kidney disease adpkd europe additional clinical trial treatment cardiovascular disease thank ground visterra company product pipeline renal domain rare hereditary disorder fluidfille sac cyst request fda eventually approve break novel drug discovery notably antiplatelet agent strive find solution unmet need nonphar form kidney gradually grow large available anxiously wait patient pletaal world oral aquaretic drug samsca maceutical area propel development cause symptom pain swollen abdomen country development groundbreaking drug establish new asset overseas example unique medical device fuse innovative technology eventually lead decline renal function half rate highly patient medical professional alike effort develop world therapeutic drug adpkd strength drug clinical research example initiative adpkd patient develop endstage renal failure age otsuka select receive corporate seeking sustained contribution unmet need include ultrasound renal denervation treatment device require dialysis kidney transplant incidence innovator award national kidney foundation rate adpkd person take aquaretic drug turn treatment patient cardiovascular renal field intend peripheral artery stent people estimate roughly patient adpkd unprecedented challenge extremely strengthen inhouse drug development core product development p japan long road single therapeutic drug incurable disease extremely encourage devel samscajinarcjynarque opment patient physicians samscajinarc development approval jynarque truly product embody motto research drug start physician say want otsuka area diuretic excretes water conventional diuretic treat edema drawback cause excretion samscajinarcjynarque water electrolyte need otsuka group future provide total healthcare human body troubling issue physician previously patient option control hamper treatment illness associate symptom adpkd like high blood pressure start research focus vasopressin high expectation firstever treatment country clinical nutrition intravenous solution diagnostic agent year later discover lead com product sell ahead intend promote fiscal sale revenue fiscal sale revenue pound lead development aquaretic drug proper use patient proceed stage today actually save life mainly monitor effect year research commence drug show treatment long period otsuka group billion billion effective adpkd mouse follow clinical trial conclude comprehensive partnership agreement finally approve roughly year journey japan kidney association purpose raise awareness year experience clinical nutrition companion diagnostic play key role identify individ world therapeutic drug adpkd adpkd improve level medical care business otsuka group continue contribute large ual difference effect drug effect reason drug take long time partnership aim assistance patient number patient lead company japan area appropriate healthcare provide otsuka group approve exist drug treat family leverage respective strength intravenous solution foray overseas provide diagnostic agent meet international standard adpkd fullscale clinical study accumulate experience party guide motto market clinical nutrition business opera include product support companion diagnostic wide conduct disease mean primary clinical otsuka continue indicator establish condition clear embrace new challenge future tion spread company worldwide busi range field digestive organ respiratory organ clinical trial conduct patient ness continues grow center basic solution business infectious disease cancer cardiovascular system go forward continue develop high valueadde companion diagnostic diagnostic test identify patient likely product meet market need world contribute benefit particular therapeutic agent determine optimal dose otsuka global healthcare path firstinclass treatment adpkd applaud effort clinical development team otsuka perseverance diligence develop tolvaptan patient adpkd launch jynarque otsuka group market share mean tolvaptan available patient adpkd japan eu north america country launch finally bring journey intravenous solution completion researcher start program addition japan testament patient healthcare provider participate clinical trial adpkd dream reality hope launch jynarque bring new option patient adpkd finally want congratulate commercial team success launch louis allesandrine vice president nephrology jynarque wish continue success bring jynarque adpkd patient mdd sale marketing otsuka america pharmaceutical inc receive award copyright iqvia robert mcquade kevin longino picture right chief executive calculate base jpm dec mat executive vice president chief strategic officer officer national kidney foundation reprint permission otsuka pharmaceutical development commercialization otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section nutraceutical business nc business social challengesstrengthsoverview support management improvement everyday health product category innovative product base scientific evidence functional beverage functional food revenue ratio business performance fiscal billion fiscal sale revenue billion fiscal sale revenue billion japan revenue operating profit functional beverage category mainly develop functional food sell nutrition product health north america innovative product base scientific evidence mainstay food mainstay product include calorie mate balanced product include pocari sweat develop nutritional food contain major nutrient give base rehydration drink concept pave birth new genre nourishment soyjoy soy bar way new ionsupply drink market tiovita drink soy bean give energy drink contain taurine vitamin carnitine nutrition soy bean lineup organic glu chloride oronamin c drink carbonate energy drink tenfree product sell country contain multiple vitamin highfiber drink europebase nutrition sant fibemini food specify health use foshu regulate gastrointestinal condition revenue sale external customer social challenge otsukas strength healthy desire people worldwide innovative product base advancement medical technology improvement scientific evidence nutritional public health helped boost global average life expectan draw knowhow accumulate pharmaceutical supplement include new product cie age population increase lifestyle disease business develop innovative product base scientific chronicphase medical care push healthcare cost evidence threaten sustainability social security scheme give seriousness issue importance manage fiscal sale revenue billion fiscal sale revenue billion health awareness base improve one daytoday health accordance cultural product category main brand nature develop unique product lifestyle habit life stage expect product value nutritional supplement free flavoring coloring equelle contain equol support women increasingly important year ahead nutraceutical create innovative new market persistently carry preservative pass rigorous qualitystan health beauty kenjanoshokutaku double support business hereinafter refer nc business help product value awareness activity campaign health field dard process procurement raw material right food specify health use slow bodys people world longevity healthy independent life relate product continue offer new value quality testing megafood supplement absorption sugar lipid reduce rise provide innovative product aim maintain improve nere inhouse research institutes external organi derive natural food source fruit vege blood glucose level triglyceride meal otc health beneficial information human health zation conduct research product launch table innate supplement market medical product like oronine h ointment treat skin ail institution ment cut cosmedic concept skincare global network brand innersignal ulos portmanteau cosmetic medicine contribute health people worldwide mutually exploit global network product attribute strength infrastructure group company share information global health issue product category change fiscal earning result material detail otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section nutraceutical business global expansion guide philosophy contribute health people worldwide engage business activity accordance culture health issue region japan north america average life expectancy japan man woman association develop new product provide selfmedication prevalent selfmedication product category high world new challenge society solution challenge undertake initiative broaden demand continue increase mainly skyrocket medi daiya food develop manufacture sell highquality emerge gap life expectancy healthy life interaction society depend circumstance cal cost recent year innovative plantbase food product cheese alternative expectancy word period person pharmavite lead company supplement industry yogurt alternative dressing dessert company product daily life hinder health problem otsuka group produce supplement base safety efficacy consulting range enjoy vegetarian people food aller draw extensive knowhow accumulate pharmaceutical expert develop product incorporate stateoftheart gy healthconscious millennial business develop innovative product base scientific evidence science company high quality supplement meet strict news world reportpharmacy time survey product category letter recent year continue conduct research quality criterion set united states pharmacopeia usp vitamin ae coenzyme q omegafish oil flax seed oil herbal supplement mood health supplement diabetic multivitamin garlic supplement cholesterol key topic extend healthy life expectancy furthermore carry lead brand recommend pharmacist management fish oil rd utilize accumulate insight coordinate activi tie promote public awareness importance hydration replenishment electrolytes prevention heatstroke activi tie teach people importance eat wellbalance meal initiative support women health goal promote health productivity management empower ment woman aim solve health issue commu nitie team local government school corporation provide information support womens health asia addition risk heatstroke tropical disease infectious establish new halalcertified manufacturing line oronamin c disease tropical region demand rise asia hydration drink soyjoy plant commence production nutrition result people play sport great sale product indonesia awareness health issue source euromonitor international retail value rsp launch pocari sweat hong kong taiwan europe expand reach set production site pocari sweat overseas sale volume case china south korea taiwan indonesia end pocari sweat available country region organic food market europe grow recent year manufacturer bc bio group catering expand worldwide healthconscious consumer demand safe trust consumer need strengthen freefrom product range indonesia launch market share worthy food accordingly socalle freefrom food alternative source euromonitor international retail value rsp sport drink category increase owe product attract attention millennialsin fiscal communitybase promotion activity effort educate meatfree food market worth approximately billion share sale indonesia consumer importance hydration electrolyte replen grow rapidly past year cagr sport drink category ishment order comply indonesia cultural norm glutenfree food market worth billion expand cagr headquarter south france nutrition sant derive french word nutrition health company manage portfolio health food brand sell product country world focus european market plant company obtain if international food pro duction standard guarantee high level product quality management construct new plant france production glutenfree food welcome organic food otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business strategy section nutraceutical business consumer product business rd framework product development base scientific evidence nc business research institute conduct research topic nutrition exercise unique view consumer product business deliver point utilize knowhow hone pharmaceutical business develop provide world familiar food beverage deli innovative product base scientific evidence maintain improve people health cious safe reassure healthy saga nutraceutical research institute otsu nutraceutical research institute establishment japans private research insti otsu nutraceuticals research institute establish tute clinical exercise nutrition facility conduct rd order research topic gut immunity partic activity subject field address exercise nutrition ular focus intestine play key role life support women health health issue large research conduct topic enhance bodys bio sale revenue business performance fiscal fiscal business overview artificial environment control room japan build insti logical barrier increase secretion immunoglobulin iga ratio billion tute enable recreation high temperaturehigh humidity antibody play crucial role mucosal immunity human sale revenue consolidate fiscal year come low temperaturelow humidity environment find clinical trial demonstrate lactic acid bacteria b heighten sale revenue operating profit billion yoy decrease mainly reflect hypoxic environment maximum altitude meter function mucosal immunity lower probability impact low domestic sale volume crystal condition far prove difficult replicate catch common cold geyser mineral water product despite new chamber help research sport nutrition yearonyear sale volume increase carbonate effect fluid nutritional intake harsh environment vitamin drink match owe high otc sale aggressive marketing strategy improve recipe mixed berry flavor berry match operating profit decrease billion yoy owe partly decline equitymethod gain revenue sale external customer topic topic world retort curry bear sterilization technology knowhow intravenous solution business science support woman vital energetic life otsuka food launch sale bon curry world effective bon curry gradually staple japanese institute discover close relationship wom commercially available curry retort pouch drawing dinner table ans health equol isoflavandiol estrogen metabolize inspiration vacuumpacke readytoeat sausage bon curry celebrate th anniversary shigeto uchiyama soy bean isoflavone bacterial flora intestine insti military apply sterilization technique date total billion pack product sell fellow saga nutraceutical tute successfully isolate lactococcus strain lactic acid knowhow group intravenous solution business base concept reliability safety product research institute bacterium produce equol lactic acid bacteria nutraceutical business division successfully develop process trial error free preservative artificial coloring otsuka pharmaceutical co ltd produce equol ferment soy germ finally create reliable safe food product easily consume vegetable ingredient series japangrown equolcontaine supplement equelle year home develop product insist bon curry product sell japan heat rd collaboration pharmaceutical division contain preservative store long period microwave oven need remove cardboard light issue expand healthy life expectancy affiliate launch equelle gele support room temperature follow product launch uncon packaging make preparation reliable safe advancement women empowerment understanding fundamental womens beauty health ventional marketing campaign enamel sign prove meal today busy family fast field women health grow increasingly important otsuka pharmaceutical continue exclude ganso bon curry limited sale okinawa otsuka pharmaceutical started lending assistance investigate possible health global joint research study cardiovascular disease benefit equol nutrition initiate explore hope offer support wom numerous possibility soy bean year en health provide information example take project elucidate relationship develop product address diet longevity study focus isoflavone con issue stage womans taine soy bean conduct saga nutraceutical research life otsuka pharmaceutical conduct broad range study maintain health woman menopausal symptom bone skin health blood vessel follow website provide information study httpswwwotsukacojpenhealthandillnesslivingwellwithmenopauseequolresearch vintage enamel sign removal sprout potato perform totally hand original retort pressure cookerspressure heat sterilization high temperature enable long shelf life use preservative otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report business expand business multilater ally focus chemical product foundation warehouse transportation value sale revenue business performance fiscal fiscal business overview creation ratio billion revenue functional chemical product increase year sale revenue operating profit year mainly owe sale volume growth product hydrazine hydrate friction material revenue fine chemical decline year year chiefly otsuka group csr impact order push transportation warehousing revenue grow year year thank society increase volume group product handle expansion share platform joint distribution environment external customer result sale revenue consolidate fiscal year come governance billion yoy operating profit billion irector audit revenue sale external customer supervisory board member topic otsuka warehouse accelerate workstyle reform initiative completion cross dock harumi building october otsuka warehouse complete renova contribute otsuka warehouse effort develop human tion yearold distribution facility harumi building resource promote workstyle reform tokyos chuo ward transform new lease office logistic crossdock facility unload different cargo multiple space origin resort item ready ship different destination suggest cross dock logistic industry term office otsuka warehouse design idea employee share information opinion broaden reach space interact different people outside company department work floor wall remove floor kitchen caf human resource development space employee openly communicate institute employee presentation give day atop institute picture establish stage time time speaker outside com aim nurture human resource unshack pany deliver lecture spot new office lead conventional idea successful fore function space enhance intellectual experience otsuka group contin productivity exchange knowledge generate uously generate innovation change building feature monument symbolic metaphorical paradigm shift includ e giant tomato tree bend giant cedar float stone otsuka holdings co ltd integrate report foundation value creation otsuka group csr realize sustainable society otsuka group recognize csr integrate business proactively promote csr base otsuka group materiality relate sdgs corporate philosophy materiality social issue goal activity relate sdgs society health unmet medical contribution unmet need promotion rd unmet need health need solution rd antituberculosis drug spread inflec eradication tuberculosis improvement drug access tion disease creation system support people health maintenance nutritional need realization healthful life improvement mainly exercise increase age healthy life extension nutrition etc enlightenment activity issue promotion problem solve strength ene partnership corporate philosophy people presentyism creation corporate culture human resource development unpaire stimulate creativity diversity promotion diversification enhance employee engagement health management quality consumption gain stakeholder trust sustainable procurement product production pursue sustainability design impairs level value chain thorough quality control stable supply sustainability establish quality assurance responsible promotional activity system safety security information provision otsukas goal deepen communication stakeholder promotion customeroriented indispensable contributor management environ climate global warming fy goal reduction reduce co emission people health worldwide ment change co emission compare value chain fy resource environmental fy goal reduction reduce environmental impact improv circula load increase simple incineration ing resource efficiency tion landfill compare fy promotion business activity aim otsukas csr mission sustainable state society earth csr integrate business otsuka group company aim water reduce freshwa fy goal improvement understand water resource risk conserva ter availability water use efficiency management effective use water grow contribute creation healthy sustainable society tion compare fy resource pursue objective support comprehensive governance system governance fragile governance longterm improvement strengthen corporate governance system corporate value thorough compliance social change risk risk identification evaluation management situation productivity badness mind body condition despite come work calculate base year support united nations global compant otsuka holding signatory un global compact way contribute realization sustainable society business activity take account ungcs principle sustainable development goal sdgs healthy planet healthy society climate changeresource circulation healthpeoplequality principle un global compact water conservation human right principle business support respect environment principle business support precautionary p p protection internationally proclaim approach environmental challenge human right principle sure complicit principle undertake initiative promote great human right abuse environmental responsibility labour principle business uphold freedom principle encourage development diffusion governance association effective recognition environmentally friendly technology right collective bargaining corporate governancecompliancerisk management principle elimination form force anti principle business work corruption p compulsory labour corruption form include extortion bribery principle effective abolition child labour principle elimination discrimination respect employment occupation otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr society society infectious disease major infectious disease worldthe consider current situation new treatment option aid malariatuberculosis single multidrugresistant tuberculosis urgently need healthy society infectious disease account high number enter publicprivate sector agreement fatality year research development global drug facility gdf stop tb partnership seek resolve global health issue total healthcare perspective otsuka pharmaceutical successfully create deltyba new pursue drug approval multiple country currently antituberculosis agent currently advance research access program deploy government public policy away deepseate preconception promote development creative human resource development expand application drug chil international institution expand access alliance pursue product quality reliability viewpoint consumer dren worldfirst new pharmaceuti ner use deltyba promote country cal multidrugresistant tuberculosis furthermore health initiative supply pharmaceutical patient aim contribute improved access pharmaceuti interruptioncontribute fair pricing country base recognition csr integrate business operation otsuka group implement csr initiative cal otsuka group engage research development create employment corporate philosophy otsukapeople create new product well health worldwide health universal desire therapeutic drug iv solution address unmet need japanese pharmaceutical company supply locally manufac people world otsuka group engage activity daily basis prevent treat disease contrib undertake initiative provide pharmaceutical ture drug risk difference technological ute maintenance improvement people health worldwide world live face host medicalrelate fair price establish healthcare infrastructure knowhow otsuka pharmaceutical factory commit issue spread infectious disease insufficient medical care facility lack effective therapeutic drug example local manufacture iv solution local manufacture iv solution base ambition supply aim solve problem constantly ask accordingly carry activity define basic pharmaceutical high clinical necessity pharmaceutical fair price country region find solution unmet medical need company address manufacturing sale continue require person rich poor equal access healthcare owe skyrocket medical cost maintain improve health issue society vision pharmaceutical industry ministry health labour welfare individual face headon alongside initiative raise awareness health individual otsuka group contribute initiative maintain improve health society large collaboration local community partnership global health innovative technology fund ghit fund drug diagnostic drug combat spread pharmaceutical business international publicprivate partnership involve japanese big infectious disease neglect tropical disease government private corporation bill melinda gate mainly develop country leverage japans high level challenge address unmet medical need foundation welcome trust united nations develop technology innovation june otsuka pharmaceu ment program specialize funding research development tical contribute ghit fund associate partner psychiatry neurology sharp rise patient central nervous system disorder unsatisfie disorder treat patient global issue highlight decision japan mini family eager try new therapeutic drug nutraceutical business try health labour welfare add psychiatric disorder key focus area otsuka group make headway field big disease psychiatric neurological disease devel psychiatric neurological disease like schizophrenia depre opment rexulti antipsychotic drug selincro drug initiative yettobeimagine need sion bipolar disorder alzheimer research decrease drink alcoholdependent development field challenge reason patient embrace challenge develop communitybase health maintenance promotion initiative onset largely unknown furthermore therapeutic drug disease curative medicine far give surge cost healthcare japans age society nutritional education prevention lifestyle disease otsuka group promote communitybase health mainte measure avoid heat disorder sport promotion women oncology nance promotion initiative disaster prevention disaster health disaster preparedness owe advancement medical science progress embrace challenge work gene therapy cellular relief activity example otsuka pharmaceutical carry company conclude partnership agreement prefec year year diagnosis treatment cancer therapy new area treatment utilize diver health awarenessraise educational activity ture japan patient effective treatment meth sity modality respond shift conven japan leverage insight knowhow area od find reason cancer remain tional treatment base characteristic common big cause death today area oncology patient treatment personalize ahead prevent heat disorder currently unmet medical need otsuka endeavor engage research development order otsuka group conduct educational activity people relatively unknown otsuka pharmaceutical engage group focus area base track record developing provide innovative therapeutic drug early possible age child senior raise awareness activity prevent treat heat disorder company anticancer agent administer orally importance replenish hydration electrolyte employee visit site seminar importance time widely available world year term heat disorder hydration electrolyte replenishment base research otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr society result laboratory area ion supply rehydration drink support organize activity com people drink seminar mainly target athlete coaches construc mittee awareness hide dehydration work tion worker factory worker people work hot con raise awareness way prevent treat dehydration otsuka group believe creation innovation sustain company growth come activity diverse dition elderly people risk heat disorder critical range employee free openminde workplace environment end aim foster corporate culture addition otsuka pharmaceutical factory sell oral rous appetite creativity invest development human resource actively promote diversity workforce establish safe work environment effort realize fair hire evaluation women health promotion employee respect human right woman continue play active role society envi ronment need establish woman remain active time engage childraise nursing care development human resource deal health issue profe sional personal life disrupt abnormal bodily rhythm anxiety physical condition particu basic policy lar care receive midlife transitional period point history innovation generate people attract talented personnel develop flourish time significant physical mental change impact otsuka group like continuously create innovation ability individual continuously women healthy life expectancy otsuka group implement initiative aim help woman lead healthy active approach live include seminar development product etc heath seminar alongside medium longterm business investment develop demonstrate respective skill development nextgeneration executive human resource establish open recruitment system selfassessment essential constantly achieve creative innovative system purpose enhancing capability sustain growth middle long term employee groupwide initiative significant growth corporate value launch otsuka pharmaceutical human resource depart otsuka global academy human resource development program ment employ system follow opinion voice otsuka health comic library aim early identify nurture talented person employee hold individual meeting employee otsuka health comic library help child nel underpin development generation make effort maximize development deepen interest understand body executive human resource development program senior lead global human resource organizational capability work health publish year ership program middle leadership program produce introduction new system centrally manage hr infor celebrate th anniversary volume run inhouse otsuka group aim mation global level employee worldwide publish year japan medical association japanese realize effective hr development collaboration play active role otsuka pharmaceutical factory society school health supervise japan pediatric association external agency program emphasize hand work enhance management skill leader recommend donate approximately ele corporate culture seeks identify kind candidate implementation degree feedback system mentary school library nationwide furthermore compar require lead otsuka group future end department manager receive multifaceted feedback ative table compare course study employee group participate multiple people differ position relationship read material child teach program area support selfdirected learn system otsuka group disclose advance condition certain otsuka health comic library post job appoint require number people aid science health class hold health educa ing launch oga selflearning syllabus apply employee satisfy requirement apply directly company tion workshops elementary school nurse school platform otsuka group employee utilize find infor offer position transfer expectation party agreement open recruitment system utilize person work otsuka group official propose heath education otsuka mation learn english improve business skill company japan aim boost employee skill motivation invigorate interaction otsuka group employee health comic library thing build educational framework system employee provide information human resource depart httpswwwotsukacomjpcomiclibrary japanese reflect characteristic group company business ment current work duty offer opinion suggestion workplace describe career plan aspiration selfassessment system member diverse workforce continue implement yearly goal develop employee skill assign disaster relief employee right job improve workplace environment light obligation company handle item need emergency iv solution pharmaceuti diversity cal food beverage actively engage disaster relief activity disaster victim assistance basic policy otsuka group actively promote diversity base belief constantly pursuit innovation endeavor estab activity wide range employee advance lish workplace environment brim diversity innovation globalization accordingly company otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr society approach daycare center locate business premise help approach concept diversity employee balance childreare work main otsuka group company health declaration reassure workplace otsuka chemical example open japan otsuka group management con initiative include formation cancer patient strive create workplace environment condu anzen dojo experiencebase safety training center tinue actively promote diversity example host employment support team taiho pharmaceutical company cive maintaining improve health employee center run training session group employee employ womens forum base thinking develop sell anticancer agent team comprise initiative otsuka holding engage activity ees overseas affiliate party aim effort diverse workforce different nationality human resource department occupational nursing aim improve health employee collaborate improve safety awareness classroom instruction race age gender disability sexual orientation need staff aim create workplace employee suffer otsuka pharmaceutical health insurance association simulation past accident center reaffirm experience group create innovative product idea drive cancer disease continue work medical professional charge health manage failure safety awareness heighten sensitivity danger company growth receive treatment establish support framework ment company activity host health develop ability anticipate thing step ahead otsuka group proclaim promotion diversity company recognize excellence award seminar group employee family hold recognition activity improve health safety educa otsuka group global code business ethic category outstanding initiative help cancer japan major city nationwide provide information tion establish safety culture otsuka chemical receive signatory women empowerment principle patient balance treatment work group initiative health introduction health th responsible care excellence award japan chemical weps set corporate principle jointly develop furthermore heartful kawauchi establish insurance association information improve industry association ungc un woman offer guidance tokushima special subsidiary otsuka pharmaceutical health employee familie activity empower woman workplace subsidiary provide place disabled people fully groupwide tokushima health project know tokj order lengthen career diverse workforce demonstrate capability start theme project create lively enhance childcare nursing care system women empowerment principle cheerful workplace alleviate risk lifestyle disease united nations global compact otsuka group company open united nations entity gender equality empowerment woman project kick approach improve health employee susceptible metabolic syndrome tokushima area majority otsuka group employ external recognition ee live work raise awareness health issue platinum kurumin kurumin platinum kurumin otsuka pharmaceutical area overall project recommend walk exercise ministry health labour welfare tokyo stock exchange factory taiho pharmaceutical offer guidance healthy eating system ministry health labour welfare certifies kurumin otsuka pharmaceutical company meet certain standard formulate notify furthermore perspective create safe tokushima health project tokj action plan base act advancement measure support raise nextgeneration child external recognition platinum kurumin certification kurumin certify company carry higherlevel initiative excellent corporation health certify otsuka holding management otsuka pharmaceutical otsuka pharmaceutical factory taiho phar ministry economy trade industry nippon kenko kaigi eruboshi otsuka chemical grade rank maceutical otsuka electronics ministry health labour welfare system recognize corporation practice jimro otsuka wellness vend exceptionally good health management system certifie company meet certain standard recog nize effort empower woman workplace act promote active participation woman workplace seminadeshiko select otsuka holding ministry economy trade industry tokyo stock exchange limit otsuka holding otsuka pharmaceutical quality system select company conform nadeshiko brand encourage women success workplace build sustainable society otsuka group seek sustainability address environmental social issue strive diversity management selection award otsuka pharmaceutical establish quality assurance structure reassurance safety stage value chain ministry economy trade industry system recognize company improve corporate value diversity management production rd procurement sale quality control health safety basic policy research development otsuka group recognize mental physical commit create safe workplace environment employee indispensable realizing continuously implement initiative maintain improve share corporate philosophy otsukapeople create health employee ethical consideration concern appropriate rd new product well health worldwide end use experimental animal verify efficacy safety relate law ordinance guideline strive uphold rd time necessary otsuka group complie scientifically valid methodology ethical consideration otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr society viewpoint animal protection welfare include experiment committee evaluate propose animal partner send response assess business identify potential risk countermeasure life animal preservation environment experiment plan appropriate base rs principle partner respect legal compliance activi principle purchase raw material multiple company safety experimenter replacementavoidance replacement animal use tie human right labor environment environmental consideration account inhouse management system develop reductionminimization number animal anticorruption measure provide feedback example otsuka pharmaceutical collaborate ecom implement rule experiment involve animal refinementminimization animal suffering base encourage csr procurement merce department suggestion environmentally establish animal experiment committee properly conduct researcher education internal inspection evalu order ensure stable supply product friendly packaging carry animal experiment breed animal ation implementation experiment involve animal perform risk assessment key raw material advance questionnaire send business partner correspond predefine criterion ethical consideration research humanderived specimen otsuka group source procurement vision policy conduct research information speciman col credibility research committee examine base corporate philosophy otsukapeople create new product well health worldwide global csr standard otsuka group lecte human body tissue blood research plan significance goal research personal conduct source procurement activity contribute build sustainable society people health improvement qol otsuka strive provide product sufficient quality innovative reliable safe otsuka group complie law guideline conduct information management system research progress status scientifically medically appropriate research consider research outcome standpoint ethical scientific relationship supplier consideration society ation ethic group company establish committee validity protection personal information build relationship trust supplier value achieve sustainable society fulfill social responsibility chain open fair communication aim mutual sustain human right labor environment support local community include outside member ensure appropriateness able growth compliance supplier selection criterion abide law regulation thoroughly eliminate select fair transparent company supplier compre unfair transaction behave high ethical standard consideration research pathogenic microorganismsgenetically modify hensively evaluate quality q cost c delivery business stability organism experiment genetically modify organism accident consideration environment production quality control use pathogenic microorganism research sample set internal rule examination contain otsuka group complie law ordi safety committee screen committee nance work prevention experimentrelate basic policy duty healthcare company customer characteristic business line pharma ethic development pursue product quality safety otsuka group ceutical food beverage chemical cosmetic establish production quality control system suit development pharmaceutical confirm safety human right personal information otsuka group imple effectiveness candidate compound conduct clinical ment clinical trial compliance ethical principle approach trial cooperation healthy individual patient standard include ichgcp international standard otsuka group production quality safety control sys business establish global product quality policy recognize importance ethical consideration implementation clinical trial pharmaceutical product tem comply legal requirement governmental area addition product quality aim industry standard include japan pharmaceutical medical improve quality clinical practice operation device act pmd act japans food sanitation act handle clinical datum constantly make improvement group work acquire international certification globally manage quality benchmark nutraceutical procurement iso quality iso medical device business utilize global network draw guideline iso fssc food safety furthermore order establish benchmark monitor quality control activity basic policy ensure thorough quality control employ traceability strive constantly improve quality mutual knowl otsuka group business partner aim legal compliance environment protection system cover stage product lifecycle raw edge inspection owe difference system regula contribute build sustainable society promote human right material procurement production distribution sale tion country region encourage csr procurement take consideration factor groupwide global production meeting hold regularly plant acquire international standard iso share issue case example relate production fssc iso environment perform approach plant order provide late information pro internal audits plant periodic basis otsuka group engage business activity safe healthy relationship formulate share duction control prevent issue occur addition inquiry product customer reliable socially acceptable compliance law business partner groupwide otsuka group source pro provide regular training relevant employee health place framework improve value regulation entire value chain commencing curement vision policy take account factor safety gmp environmental protection food safety product specifically confirm product quality dealing business partner perform screen human right labor issue environment anticorruption compliance iso standard department product lot manufacture check ensure quality raw material guarantee measure formulate source procurement major group company operate global scale analyze return item compare product stable procurement conclude basic transaction agree guideline embody provision policy plan establish operate global quality assurance sys storage plant analyze cause issue come ment advance case new supplier transaction hold information session future business partner tem instance global product quality meeting hold future countermeasure determine carry diligence conduct survey business partner csr otsuka pharmaceutical attend good manufacturing practice hand seek mutually sustainable development fair procurement selfassessment questionnaire provide un people include manager quality supervisor discuss equitable transparent procurement establishment global compact network japanin quality issue future initiative pharmaceutical otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr society sale alike periodically share detail inquiry specific opin focus relate law regulation inquiry ion user product safety information sale opinion customer submit relevant depart basic policy staff safety control department quality assurance depart ment feedback reflect future product development believe otsuka group obligate provide high suitable legally compliant promotion advertising ment analyze inquiry receive customer improvement example taiho pharmaceutical adopt ervalue product service customer engage communicate customer appropriate manner step improve product provide example new specification reduce sharpness edge otsuka pharmaceutical receive inquiry meptin aero individual case exterior cardboard packaging tiovita approach pharmaceutical business sol inhaler treat asthma attack discover series customer cut finger open product fail spray function properly mainly e product otsuka group expand jpma promotion code standard report regulatory authority develop foreign substance enter inhal inquiry defective product return item prescription drugsa code behavior healthcare profe revise document establish system mouthpiece dose counter tick analyze quality control department compare sionalsto formulate code practice allow constantly perform pharmacovigilance pv user fail press far result product storage consider countermeasure group company effort engage appropriate collabora global level collect assess product safety information change product label improvement light reason defect tion base relationship trust stakeholder includ include effect way continue swiftly provide internal structure otsuka group make effort daily basis e medical practitioner give clarification result monitor medical institution etc nutraceutical business dedicate department conscientiously swiftly respond customer inquiry relationship pharmaceutical company healthcare sure activity continue hitch implement product line group company handle feedback manner easy understand instance organization matter social responsibility strive training year relevant personnel example otsuka customer inquiry hold periodic employee training session otsuka pharmaceutical leverage use artificial ensure adherence standard order fulfill responsibility pharmaceutical addition aforementione training intelligence ai provide customer well quality pharmaceutical company ensure practice proper company conduct annual training relate pv employee service ai system offer common highpriority medical care base ethic patientoriente commitment base thinking employee accountable response base nature customer inquiry product spray dose furthermore addition abide legislation country ensure safety pharmaceutical product counter fail tick user enable operator respond quickly accurately example japan japans pharmaceutical medical device good quality practice press way inhaler good vigilance practice reason include easytoread act pmd act engage quality control postmanufac pharmacovigilance instruction outside inhaler ask user press way ture safety control accordance gqp gvp measure counterfeit drug counterfeit drug issue international collaborate market surveillance agency industry body community fail provide expect thera government make effort ensure patient peutic effect patient health life risk safety sure pharmaceutical reach hand combat counterfeit drug otsuka launch global patient appropriate distribution channel guar product security team involve overseas group compa antee product quality ny prepare structure deal countermeasure pharmaceutical product deceptively represent authenticity origin declaration customercentric commitment drug contain ingredient show label contain active ingredient show label corporate philosophy inculcate value employee approach nutraceutical business consumer product business spirit corporate philosophy otsukapeople create new grow business draw power highly product well health worldwide otsuka group company diverse workforce remain committed foster social similar fashion pharmaceutical business estab otsuka pharmaceutical develop product provide innovative product service contribute reward business mindfulness employee stay abreast ing healthy live people aim maintain trust prevail value true customer need order create new catego lishe dedicated unit comprise multiple department deliver health value base scientific ground estab customer society rie product service review marketing plan sale promotion material prod lishe scientific affair department gather dissemi interactive communication customer uct nutraceutical consumer product business nate information product relate knowledge policy apply knowledge knowhow accumulate year commitment leader research business conduct mutual communication activity ensure marketing sale promotion activity late academic information department hold monthly conduct daily business constant attentiveness include seminar factory tour online communication encour appropriate comply law regulation information session employee patient customer truly desire continue uphold otsukas age people aware inform health culture actualization creativity company involve establish point contact inquiry consultation aspect health treatment illness maintenance feedback enhance product service communication patient medical professional customer promotion healthy lifestyle dedicated coordination cooperation rapid problemsolve indispensable company contribute well health quality life healthrelate company patient consumer people globe prioritize safety product issue come light otsuka group recognize enhance mutual communi customercentric commitment clearly express stance corporate governance marshal resource quickly efficiently provide cation customer respond opinion undertake initiative basic policy dictate fulfill social responsibility solution develop everbetter product service sincerity improve value product pharmaceutical business order minimize prob honest trustworthy dialogue customer business collaborator october employee local community shareholder extension contribute people health society local lem risk associate product quality safety transparent fair timely decisionmake community publish declaration usability experience patient healthcare professional otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr environment environment thirdparty verification ghg emission order improve transparency reliability environ ghg emission value chain fiscal healthy planet mental datum otsuka group subject verification emission scope greenhouse gas ghg emission scope category category aim indispensable company contribute health global people otsuka group scope thirdparty organization implement initiative aim understanding improve category scope policy engage business activity voluntarily positively continuously creativity consider global emission use trend emission continue expand scope sell product environment value chain commit shape sustainable society verification enhance reliability datum thousand tonsco scope scope direct emission scope indirect emission energy source category otsuka group global environmental council scope indirect emission emission purchase good service company otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceu tical otsuka chemical otsuka food group global company contribute health demand global society deepen understand people worldwide otsuka group work sincerely reduce recognition environmental problem environmen resource circulation impact global environment busi tal education employee enhance collabora fy goal reduction simple incineration landfill compare fy ness hope contribute creation sustainable tion group company society protect nature future earth aiming achieve sound materialcycle society work improve resource usage efficiency reduce gener otsuka group global environmental councilcompris ation waste promote r reduce reuse recycle initiative achieve final waste disposal volume close zero ing director otsuka holding executive officer effort realize zero emission inhouse definition recycling rate council organization group company secretariatformulate otsuka group environmental policy guideline advance initiative groupwide coordinator initiative aim zero emission resource recycling rate final disposal environmental management collaboration otsuka holding director ton otsuka group company otsuka group company carry material recycling otsuka group identify climate change resource thermal recycling generate waste require circulation water conservation csr materiality secretariat fiscal group company japan achieve zero environmental initiative kick deliberation emission recycling rate reduce otsuka holding formulation longterm environmental vision consis otsuka pharmaceutical total waste volume ton yearonyear tent principle united nations global compact reduction group continue work bring information disclosure global standard set waste minimize disposal volume activity mediumterm environmental target specific action plan council member enhance efficient use resource business slate launch otsuka otsuka taiho otsuka otsuka otsuka th e p ur ec oe fs ti hn eg r man ad l er neu ers ge gf ew na es rt ae ea ds fr ra ow ina ct ie nr eia ral io n n og f r d ai se tn et look ahead strengthen practice environman pharmaceu pharmaceu pharmaceu chemical warehouse food major consolidated subsidiary japan tical tical factory tical tal management meet social responsibility water conservation fy goal improvement water use efficiency compare fy climate change fy goal reduction co emission compare fy otsuka group identify water resource csr materiality environmental initiative evaluate waterre late issue water key production site world otsuka group encourage regionally appropriate management efficient water usage goal conserve improve water resource recognize otsuka group conduct business global scale face significant risk impact climate change accordingly formulate longterm reduction target action plan achieve target aim realize carbonfree society promote thorough energysaving measure endeavor alleviate impact evaluate water risk production water usage water use efficiency environment use renewable energy site thousand thousand million otsuka group conduct water risk assessment initiative energy use optimization co reduction evaluation production site water risk evalua tokushima prefecture production site group emission group include use joint crediting tion tool aqueduct develop world resource insti concentrated otsuka chemical otsuka pharmaceutical mechanism jcm installation highly efficient equip tute wri understand reduce impact factory supply electricity steam neighboring group com ment pt otsuka indonesia waterrelate business activity panie use cogeneration system instal initia system work develop country reduce greenhouse gas emission calculate otsuka group consolidate subsidiary company include tive overseas promote efficient energy use reduce co w jah pi ac nh result reduction assess contribution partner country energyderive co emission producer outside japan japan otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr governance governance initiative strengthen corporate governance level director remuneration corporate gover establishment otsuka holding co ltd nance issue report board director term director set year decision adopt director retirement benefit system committee consist ceo director charge admin corporate officer system adopt outside audit supervisory board member istration outside director currently ceo outside audit supervisory board member stock option performancelinke remuneration introduce serve chair committee addition improve management soundness work improve corporate ethic work stock publicly list december policy mediumterm management plan announce appropriate risk management outside director outside audit supervisory board member e audit supervisory board member audit second mediumterm management plan announce supervisory board outside director outside audit supervisory board member otsuka group global code business ethic establish audit supervisory board member attend express opinion corporate governance corporate governance guideline establish internal whistleblowing system establish externally otsuka holding major meeting board director monitor legality group company outside director outside audit supervisory board member soundness management show performance effectiveness board director evaluate basic position corporate governance stock option conditional progress mediumterm management plan dutie director audits perform audit supervisory introduce otsuka holding commit promote sustainable increase business partner employee local community sharehold corporate governance guideline revised board core process strive improve corporate governance committee establish corporate value medium longterm realize er ongoing dialogue company articulate basic effectiveness board director evaluate base questionnaire complete effectiveness audits audit supervisory board member director audit supervisory board member corporate philosophy otsukapeople create new product approach corporate governance corporate governance report meeting hold outside director outside audit supervisory board share information exchange opinion appropriate member improve understand group management business well health worldwide meet commitment guideline female director relevant department internal audit department internal corporate governance guideline revise adopt basic policy make transparent fair timely control department administration department finance restrict stock compensation plan introduce decision fulfil corporate social responsibility live corporate governance guideline accounting department accounting auditor expectation stakeholder include customer httpswwwotsukacomencompanygovernancepdfguidelinepdf corporate organization company adopt statutory auditor system f evaluation effectiveness board director overview corporate governance structure company board director audit supervisory january february year company con board engage account auditor article duct questionnaire survey director audit board director include outside director governance system quick reference march incorporation stipulate number director shall supervisory board member base outcome advance execution management plan supervise form organization company audit exceed number audit supervisory board survey company perform examination evaluation company management assume role responsibili supervisory board member shall exceed board director meet march follow review tie enhance profitability capital investment efficiency board director company attorney order promote sustainable growth company outside director independent directors b board director summary evaluation fiscal increase corporate value medium longterm board director convenes month regularly result analysis evaluation overall effective term director year company secure soundness establish solid hold extraordinary meeting necessary important ness board director fiscal summarize audit supervisory board corporate governance structure live social expectation member business decision supervise execution operation board member express opinion collab ensure audit supervisory board member oration outside director audit supervisory outside audit supervi independent director independent board director audit sory board member c director selection criterion board need enhance confirm meeting director performance duty collaboration accounting auditor deloitte touche tohmatsu llc company aim indispensable contributor audit supervisory board outside director accounting auditor internal audit department people health worldwide target sustained growth opportunity exchange opinion man enhance corporate value medium long term help agement outside director hold regularly achieve goal ensure diversity director serve improve communication ahead shareholder meeting company appoint adequate people directorspeople result revise information provide board electsdismisse electsdismisse electsdismisse insight advanced expertise extensive experience con member improvement meeting consult ducive realize maintain appropriate effective board director managed assess favorably corporate board director operational audits audit g co ov mrn ia ttn ec ee recommend director include outside director accounting audit u ap ue dr itv oi rs inry cl ub ina gr corporate governance particularly internal director confirm deliberation meeting appointsdismisse outside member comprehensively evaluate experience expertise insight enhance ahead take account opinion attribute candidate ensure quali board member president representative cooperates director ceo cooperate tie require implement group corporate philosophy confirm system monitor execution code business ethic corporate strategy corporate strategy business need instruct report accounting audits accounting auditor enhance improvement internal audit department corporate governance committee believe assessment indicate board cooperate seek increase management transparency objectiv director function properly term effectiveness ity company establish corporate governance committee strive improvement issue high approval meeting prior material matter group board consultation february advisory body board director light evaluation examination increase board management corporate ex post facto guidance auditor report committee discusses deliberate nomination effectiveness effort deepen corpo director audit supervisory board member structure rate governance company subsidiarie shareholder meeting board director audit supervisory board member etc otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr governance g independent director auditor otsuka group company past establish h internal audit department assess internal control basic approach internal con select outside director outside audit supervisory independence standard outside director order ensure company internal audit department report directly trol system establishment describe corporate board member company look individual great independence standard set corporate president department regularly conduct audits base governance report submit tse deal knowledge extensive experience field governance guideline apply outside audit internal audit rule verify operation exe company require candidate ability adequately supervisory board member furthermore give outside cut appropriately efficiently regard asset j accounting audit exercise management oversight function fair objec director outside audit supervisory board member satisfy business general company affiliate company otsuka holding sign auditing agreement tive monitoring supervision auditing management requirement independent directorsauditor prescribed department submit audit report president director audit firm deloitte touche tohmatsu llc accounting auditor neutral objective viewpoint addition require tokyo stock exchange tse company register audit supervisory board member need audit company account fair impartial stance outside director involve business execution tse improvement indicate department recommend action certify public accountant audit company take afterward confirm status impleman account tsutomu hirose koichi niki ichiro matsunaga rationale selection outside director auditor tation order optimize business execution department assist certify public accountant time attend fy share information cooperate audit supervisory people certify public accountant rationale selection dbo ira er cd rf vu d soit r b ou ap dr board member accounting auditor audit company account continuously meet meeting seven year omit description mr matsutani give effective advice company manager neutral internal control department expert perspective outside director abundant experience extensive knowledge yukio medical welfare field expertise healthcare industry risk company internal control department handle internal k succession plan matsutani conflict interest visvis general shareholder company believe mr mat control financial reporting company order identify talented personnel early systematically sutani suitable independent director affiliate company department formulate rule man develop nextgeneration executive equipped quality company anticipate give abundant experience extensive knowledge corpo rate manager expertise pharmaceutical industry mr sekiguchi able ual pertain internal control provide training skill require corporate philosophy otsuka holding outside ko director sekiguchi effective advice appropriate company manager neutral expert perspec ensure employee thoroughly understand operational rule continuously build implement nextgeneration executive tive outside director risk conflict interest visvis general shareholder company believe mr sekiguchi suitable independent director department work cooperation internal audit development program regularly report progress department continuously monitor status operation board director company anticipate give abundant experience track record insight corpo rate manager ample experience expertise network food industry mr aoki establish system executive reliably yoshihisa human resource development p able provide beneficial shrewd advice company management objec aoki tive expert perspective outside director risk conflict interest general shareholder company believe mr aoki suitable independent director remuneration director auditor mr sugawara specialized knowledge certify public accountant abundant business experience company determine able use experience hiroshi expertise audits company risk conflict interest visvis general sugawara shareholders company designate mr sugawara independent audit remuneration system director auditor design management plan combine multiple condition earning supervisory board member company attract retain talented personnel achievement base earning indicator rd medi outside attorney ms wachi wellverse corporate legal affair company deter strongly motivate perform duty contrib umterm management plan audit yoko mine able use experience expertise audits company supervisory wachi risk conflict interest visvis general shareholder company ute sustained improvement group earning board member designate ms wachi independent audit supervisory board member corporate value b remuneration director subsidiary oper mr takahashi hold major position internal control department year ate company kazuo abundant experience corporate management company determine director remuneration company hold remuneration director subsidiary operate compa able use experience expertise audits company takahashi risk conflict interest visvis general shareholder company designate ing company ny determine base duty responsibilitie mr takahashi independent audit supervisory board member remuneration director otsuka holding hold com execution business base group strategy formulate number board director meeting audit supervisory board meeting attend outside director yoshihisa aoki list newly appoint th pany consist fix remuneration accord title posi otsuka holding dutie responsibility involve general meeting shareholder hold march tion bonus link performance provide shortterm formulation strategy operate company incentive stockbase compensation provide strengthen corporate governance exceed independence standard outside director corporate governance guideline medium longterm incentive begin fiscal cap director remuneration resolve general meeting replace stock option restrict stockbased shareholder note restrict stockbase compensation company determine outside director independent follow apply compensation system incentive plan achieve sustained system newly implement fiscal apply person relative second degree kinship outside director currently past fiscal year man growth medium longterm earning corporate value roughly director exclude outside director age director executive officer executive operating officer important employee executive company company subsidiary restrict stock issue system com group major subsidiary company outside director belong executive transaction otsuka group pensation system reflect attainment mediumterm transaction fiscal year past fiscal year exceed consolidated net sale company outside director legal accounting tax expert consultant receive remuneration exceed million fiscal year directly otsuka group exclude remuneration company outside director fiscal year past year donation nonprofit organization outside director belong executive otsuka group exceed million total past fiscal year exceed income nonprofit organization otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation otsuka group csr governance c remuneration auditor company total remuneration officer category total remuneration evade payment taxis group endeavor parency trust deal tax authority worldwide type number applicable officer audit supervisory board member essentially pay appropriately disclose information ensure degree trans basic remuneration variable component base total total remuneration type number earning co atf ef gic oe rr n er e mr eam ilt c liu oo nn remb tu ia ons ni ec ra cc h oa pm r tgoi f il e l u si tn sn c k bonus reo r bf w tf c u iai oehc nsi ne iv ecr e rs risk management director exclude basic policy outside director otsuka group carry risk management supervi management efficiency control risk inherent audit super sion management base recognition pursue business activity key enhance corporate value visory board member exclude risk management system outside audit supervisory establish risk management system otsuka group leverage control place risk board member place risk management policy set risk management department risk management committee outside directors management committee comprise director charge assess comprehensively manage risk jeopardize administration president representative director chair enhancement group sustain corporate value compliance approach basic policy individually assess risk business risk pose risk organization training relate legal compliance form cornerstone business activi aim achieve sustained growth earn trust management officer perform analyse evaluation formu topic corruption prevention protection tie otsuka group possess high ethical standard customer conduct business activity honestly late execute action plan aim meet objec human right base otsuka group global code busi tive target organization periodically ness ethic approach regularly hold approach implement employee training reference event drill prepare unexpected contingency like disaster otsuka group establish otsuka group global code regular meeting hold progress initiative business ethic openly publish information country share compliance officer otsuka hold business continuity planning management stance initiative line code website ing visit overseas group company gather informa otsuka group business continuity plan bcp place bcm standpoint organization equip form message president otsuka holding tion offer suggestion improvement ensure group continue operate effectively infallible business continuity capability collaboration draw otsuka group global anticorruption diligence policy force group com possible maintain stable supply product mainly otsuka pharmaceutical otsuka pharmaceutical policy represent stance prevent corruption panie conduct diligence new business partner largescale earthquake disaster strike factory taiho pharmaceutical otsuka warehouse site worldwide accordingly continue conduct purpose assess risk relate corruption perspective business continuity management bcm otsuka make effort strengthen countermeasure business activity base strong sense ethic hold otsuka holding lead group company holding group company jointly construct system otsuka group continue universal training session year base take step establish internal whistleblowing system groupwide business continuity framework gradually business activity well possible guarantee stable prod content aforementione code policythey access company external loca expand scope framework acquire iso uct supply time disaster major attend employee subsidiary prepare materi tion office attorney rule allow certification august production stable supply group company jointly conduct desktop simulation drill al english chinese indonesian addition japanese whistleblowe fulltime employee con medicinal product beverage food acquire assumption earthquake epicenter directly furthermore detail training session report tract dispatch parttime employee rest certification stable supply infusion solution april tokyo drill provide opportunity test regularly board director otsuka holdings internal assure know information follow stable supply anticancer drug collaborative framework base topic ensure stable compliancerelated audits implement periodically report strictly manage prevent negative repercus acquisition iso certification demonstrate product supply group company result report board sion information relate internal whistleblowing system director initiative overseas compliance officer major group company report regularly board information security appoint group company asia director meeting otsuka holding strive raise level constantly improve compre construct datum otsuka group establish man hensive security group set otsuka group infor agement system protect sensitive personal information mation security committee facilitate sharing uptodate customer acquire personal information protection tax compliance security information examination specific security management system privacymark certification information measure order counter risk cyberattack security management system ism certification busi basic policy otsuka group employ number measure arrange ness appropriate otsuka establish eu general otsuka group operate country world contribute local economy country region system security audits external specialist diagnose website datum protection regulation compliance policy concern recognize appropriate payment taxis accordance otsuka group fulfill tax obligation accordance vulnerability conduct drill relate targeted email attack e general datum protection regulation gdpr group relevant law regulation country region otsuka group global code business ethic monitor post social medium addition group wide initiative information security conduct regular emergency drill focus core system approach otsuka group complie aforementione code international taxation rule submit tax declaration correctly ethic tax policy countryspecific law tax convention pay corporate tax engaging transaction design otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report foundation value creation director audit supervisory board member march leave noriko tojo yoshihisa aoki sadanobu tobe yukio matsutani yoshiro matsuo ko sekiguchi ichiro otsuka tatsuo higuchi yozo toba yuko makino hiroshi sugawara shuichi takagi yoko wachi atsumasa makise kazuo takahashi masayuki kobayashi directors chairman representative director president representative director ceo senior managing director outside director outside director outside director ichiro otsuka tatsuo higuchi yoshiro matsuo yukio matsutani ko sekiguchi yoshihisa aoki apr join otsuka pharmaceutical factory inc mar join otsuka pharmaceutical co ltd apr join otsuka pharmaceutical co ltd apr intern pediatric department st lukes international hospital apr join mitsubishi corporation apr join itochu corporation june e xecutive director director consumer product development june enior manage director otsuka pharmaceutical co ltd jan v ice president associate general manager general affairs oct j oine ministry health welfare present day ministry join boston consulting group june executive officer itochu corporation division otsuka pharmaceutical co ltd pharmavite department otsuka pharmaceutical co ltd health labour welfare jan g eneral manager sterrad business division johnson johnson apr anage executive officer president food company itochu june anage director responsible consumer product publicity nov e xecutive deputy president executive director otsuka june v ice president general manager general affairs department aug irectorgeneral health policy bureau ministry health labour medical k k present day johnson johnson k k medical corporation promotion development division otsuka pharmaceutical co ltd pharmaceutical co ltd otsuka pharmaceutical co ltd welfare company apr ember board senior manage executive officer president dec e xecutive director research development otsuka pharmaceuti june e xecutive director responsible business otsuka pharmaceu nov enior vice president general manager general affairs aug director national sanatorium tama zenshoen nov p resident representative director janssen kyowa co ltd food company itochu corporation cal factory inc tical co ltd department additional responsibility legal affair apr president national institute public health present day janssen pharmaceutical k k mar administrative officer itochu corporation current position representative director otsuka pharmaceutical factory inc june p resident representative director otsuka pharmaceutical co external relation otsuka pharmaceutical co ltd dec v ice president international university health welfare july chairman director janssen kyowa co ltd june outside director arata corporation current position dec e xecutive deputy president representative director otsuka ltd july anage director corporate administration otsuka holding co current position oct supreme advisor janssen kyowa co ltd mar outside director otsuka holdings co ltd current position pharmaceutical factory inc june executive director otsuka pharmaceutical co ltd ltd mar outside director otsuka holdings co ltd current position jan r epresentative director dia japan present day sh dia japan dec p resident representative director otsuka pharmaceutical july p resident representative director ceo otsuka holding co mar enior manage director corporate administration otsuka apr utside director nic corporation present day solasto corpora factory inc ltd current position holdings co ltd tion current position july executive director otsuka holdings co ltd dec executive director otsuka chemical co ltd jan e xecutive director otsuka medical devices co ltd current mar outside director kenedix inc june e xecutive deputy president executive director otsuka holding feb p resident representative director otsuka pharmaceutical co position mar outside director otsuka holdings co ltd current position co ltd ltd current position mar enior manage director otsuka holdings co ltd current june r epresentative director otsuka pharmaceutical factory inc position vice chairman representative director otsuka holdings co ltd mar e xecutive director otsuka pharmaceutical co ltd current position chairman otsuka pharmaceutical factory inc current position chairman representative director otsuka holdings co ltd current position executive director cfo executive director executive director yuko makino sadanobu tobe atsumasa makise apr join otsuka pharmaceutical co ltd apr enior manage director representative director shinko food dec join otsuka pharmaceutical co ltd audit supervisory board member apr join baxter limited co ltd present day otsuka foods co ltd june v ice president director odpi division otsuka pharmaceutical apr join otsuka pharmaceutical co ltd july e xecutive deputy president representative director otsuka co ltd mar irector corporate finance accounting department otsuka foods co ltd june v ice president director finance department oiaa division holding co ltd nov e xecutive deputy president representative director otsuka otsuka pharmaceutical co ltd stand audit outside audit outside audit outside audit supervisory sept v ice president director corporate finance accounting chemical holdings co ltd present day otsuka chemical co ltd june anage director finance accounting otsuka pharmaceutical supervisory board member supervisory board member supervisory board member board member department otsuka holdings co ltd p resident representative director otsuka chemical holdings co ltd vice president director accounting department otsuka co ltd july enior manage director corporate finance otsuka holding co yozo toba hiroshi sugawara yoko wachi kazuo takahashi pharmaceutical co ltd july executive director otsuka holdings co ltd ltd apr v ice president director tax department otsuka holdings co june vice chairman representative director otsuka foods co ltd chairman ceo otsuka america inc apr join otsuka chemical co ltd oct join chuo audit corporation apr r egistere attorney law daiichi tokyo apr j oine ebaraudylite co ltd present day ltd june chairman representative director otsuka chemical co ltd apr chairman otsuka america inc jan irector information center otsuka chemical oct j oine deloitte touche tohmatsu present day bar association jcu corporation vice president director finance accounting department june vice chairman otsuka foods co ltd mar executive director otsuka foods co ltd co ltd deloitte touche tohmatsu llc join kajitani law office current mar e xecutive director strategic plan ra otsuka pharmaceutical co ltd june tanding audit supervisory board member otsuka holdings co mar p resident representative director otsuka foods co ltd jan cfo trocellen gmbh feb v ice president capital management co position institute co ltd mar e xecutive director corporate finance otsuka holdings co ltd ltd current position perate officer information system ltd current position june c orporate auditor nichia corporation nov e xecutive director general manager mar executive director cfo otsuka holdings co ltd current position nov president representative director otsuka foods co ltd executive director otsuka holdings co ltd current position department otsuka chemical holding co june utside audit supervisory board member current position system division sunkus associates inc june executive director otsuka holdings co ltd current position ltd present day otsuka chemical co ltd otsuka holdings co ltd current position mar utside audit supervisory board member oct e xecutive director head information mar chairman otsuka foods co ltd june c orporate officer director corporate june utside audit supervisory board member otsuka holdings co ltd current position system division circle k sunkus co ltd mar executive director otsuka foods co ltd current position f hi la dn ince g c oc c lo tu dn ting department otsuka oct uts tu sik da e p dh ia rerm cta oc nu pic pa ol nco p l rt kd ing develop e tx ac tu et giv e ffi ir ce ec hr e c ch uie stf oo mf eth r e fra na cg ism ee en executive director business portfolio dec e xecutive director corporate administration ment co ltd relations office internal control executive director executive director management accounting otsuka chemical co ltd mar udit supervisory board member otsuka e sun nvi kr uo sn coe n la tl anagement office circle k mar e xecutive vice president corporate finance pharmaceutical co ltd current position masayuki kobayashi noriko tojo shuichi takagi accounting corporate service department e xecutive director head area franchise otsuka holdings co ltd circle k sunkus co ltd auct g j p rein se idd e na ti h ip hh oa prm haa rc meu uic sa al c io n c l pd r esent day taiho oncology ap ur g j jo oi ne ed g sho eld rsoa nn ls ea hch ms nja bp ra th ec ro r hpo ldat inio gn inc sep pr j j oi ne ed oo tsb uis kh pm ha rc mo ar cep uo tr ica l co ltd mar ot ta sn ud ki g h oa lu dd init g cs ou p e lr tv di cry u rb reo na tr p om se itm iob ne r ay r e od x uve tic ssu ii dot ei nv e c ud dri cr ite le c ko r u uh pn ee k ra vud ocf ro yi n b f l oo ar dm r da mtio en es rt e ms inc july engagement manager mckinsey company japan office aug f inance department oiaa division otsuka pharmaceutical co otsuka holdings co ltd current position sept executive director taiho pharmaceutical co ltd june director intel capital japan intel corporation ltd apr president ceo otsuka america inc aug manage director corporate development otsuka holdings co ltd july c orporate finance accounting department otsuka pharmaceuti apr p resident representative director taiho pharmaceutical co ltd feb executive director otsuka medical devices co ltd cal co ltd mp ar r c e ec xx hu ee cr c ir uu ttn ii vv ee np ddo ts ii rri eet ii h cco ttn oo rr ona ti c sh uoo k lp ao h hga ym l ia n u c gss cc ou rn rc le tn dt p cos ui rt rio enn position jap u nr g p e p ltxr r de ee sc ud cte e uivn n ret r e ad nn ni trd e p cc r ot ipo r ir oa e nsd e ts n cu tak e ta va epm h de irr r ei mc ta ov rin e oc tl sl uc ka medical device co jana ar v c st f ia eci ec c naoe l io p ir nc rr l ii crni d e sc pe po rn rvt e asr su te ie dks ep l ip tn r iis tv pi eb rd etle e dlo emr n tn e sd di oa fpb fir cu e es en tts u ko os hu ok lua dk ip nah g pa sh r cm ora c e lu tc deti uca l executive director otsuka america inc mar e xecutive director business portfolio management otsuka holdings aug chairman pharmavite llc co ltd current position mar executive director otsuka holdings co ltd current position otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report datum section main datum effect fiscal end december otsuka adopt international financial reporting standard ifrs information fiscal end december present line ifrs billion yen billion yen million dollar jgaap jgaap ifrs ifrs item result revenue operation sell general administrative expense research development expense rd ratio operating profit operating profit margin profit attributable owner company financial total asset position total equity ratio equity attributable owner company total asset roe cash flow net cash flow operating activity net cash flow invest activity free cash flow dividend annual dividend share yen dividend payout ratio common stock number share outstanding yearend thousand stock price share stock price yearend yen number total person employee japan person outside japan person female manager number female manager person ratio female manager ratio e dn av ti ar n mental total co emission tt oh su csa japan outside japan co emission sale ton million water usage thousand resource recycling rate item name accord ifrs number employee otsuka holding subsidiary december sga expense jgaap present total expense rd expense company believe useful investor compare company financial result company nonconsolidate otsuka pharmaceutical otsuka pharmaceutical factory taiho pharmaceutical otsuka chemical otsuka warehouse otsuka food jgaap ifrs environmental datum limit past year change collation criterion change consolidate fiscal year fiscal end december transitional period cover month april december calculate consolidated subsidiary otsuka group company constitute co emission originate energy dollar amount report represent translation japanese yen solely reader convenience rate approximate exchange rate december figure major consolidated subsidiary japan otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report datum section management discussion analysis consolidate financial result fiscal market environment eb guadecitabine development code sgi year increase mainly increase property plant previous fiscal year net cash provide operating activity environment surround healthcare industry currently currently develop treatment atten equipment million yen goodwill million million yen fiscal net cash invest experience period change particular age society tion deficit hyperactivity disorder adhd acute myeloid yen intangible asset million yen defer tax ing activity million yen investment introduction expensive drug outbreak infectious leukemia aml respectively asset million yen decrease future include acquisition remain share disease contribute everincrease health care budget sell general administrative expense current financial asset million yen recor medical inc acquisition visterra inc net cash make government japan united states fiscal year include impairment loss million yen financing activity million yen result europe aware cost medical treatment intangible asset trademark marketing right etc liability dividend payment yen share shareholder face limited financial resource medical guideline termination license agreement onzetra xsail generic total liability december million million yen total repayment noncurrent borrowing catch balance cost benefit treat sumatriptan addition fiscal year avanir pharma yen increase million yen compare million yen result total cash ment penetration generic drug reform ceuticals inc californiabase subsidiary otsuka group million yen end previous fiscal year increase outflow invest financing activity exceed operat drug pricing system continue progress expensive reach agreement principle resolve unite mainly million yen current noncurrent e cash inflow medical treatment new technology emerge states department justice investigation relate certain contract liability result application ifrs total bond borrowing december circumstance need steadily increase avanir past sale marketing practice product fiscal million yen decrease million yen exceed total daily measure disease prevention balanced life plan nuedexta agreement principle avanir current noncurrent bond borrowing cash cash equivalent group maintain include nutrition addition exercise rest united states contingent party negotiation schedule payment borrowing acquisition avanir financial soundness otsuka group operation encompass core busi execution civil criminal administrative agreement pharmaceuticals inc status group cash flow fiscal ness pharmaceutical business provide comprehen estimate fine damage disgorgement restitution legal contribute factor follow sive health support diagnosis disease treatment fee interest charge total approximately million current liability nutraceutical business assist people maintain accrue previous fiscal year total current liability december cash flow operating activity improve daytoday health response grow fiscal year accrue remain million million yen increase million yen compare net cash provide operating activity fiscal amount awareness health reconfirming strong belief sell general administrative expense million yen end previous fiscal year million yen contribute factor importance total health care include disease prevention increase mainly increase trade payable million yen profit taxis million yen deprecia financial position million yen contract liabilitie million yen tion amortization expense million yen impair status revenue accompany application ifrs fiscal ment loss reversal impairment loss million yen fiscal year end december asset current liability million yen share profit associate million yen increase otsuka group record consolidated revenue total asset december million trade receivables million yen income million yen previous fiscal year operat yen decrease million yen compare noncurrent liability taxis pay ing profit million yen profit year million yen end previous fiscal year current asset total noncurrent liability december million yen profit attributable decrease million yen noncurrent asset million yen increase million yen compare cash flow investing activity owner company million yen increase million yen decrease current million yen end previous fiscal year net cash investing activity fiscal amount strong growth global product new product lineup asset increase noncurrent asset mainly increase mainly increase contract liability million yen main investing activity include contribute favorably increase revenue group achieve fact group cashonhand finance acqui million yen application ifrs fiscal million yen payment acquisition property plant growth operating profit actively invest rd sition remain share recor medical inc decrease bond borrowings equipment million yen payment acquisition profit attributable owner company decrease acquisition visterra inc million yen intangible asset million yen proceed sale previous fiscal year mainly tax reform redemption investment million yen payment equity transient impact reverse income tax expense current asset acquisition investment million yen payment profit exclude impact profit attributable owner total current asset december amount total equity december million yen acquisition subsidiary million yen decrease company current fiscal year par million yen decrease million yen compare decrease million yen compare million time deposit payment acquisition subsidiary previous fiscal year million yen end previous fiscal year yen end previous fiscal year decrease primarily acquisition remain share recor current fiscal year million yen recog decrease mainly decrease cash cash mainly million yen decrease retain earnings medical inc acquisition visterra inc nize income relate transaction equivalent million yen financial asset result million yen payment dividend group acquire remain share recor medical inc million yen offset increase trade million yen profit attributable owner company cash flow financing activity transform company wholly own subsidiary receivable million yen inventory million yen impact application ifrs net cash financing activity fiscal amounted reevaluate exist shareholde contractual right million yen million yen decrease component equity million yen main financing activity include recor medical inc accordance ifrs stock market exchange rate fluctuation million yen proceed noncurrent borrowing addition impairment loss million yen noncurrent asset million yen repayment noncurrent borrowing status cash flow intangible asset inprocess research development total noncurrent asset december million yen dividend pay record rd expense result revise future profit million yen increase million yen com cash cash equivalent december decrease ability projection centanafadine development code pare million yen end previous fiscal million yen million yen end otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report datum section consolidate financial statement otsuka holding subsidiary year end december consolidate statement financial position billion yen million dollar billion yen million dollar asset liabilitie equity current asset liabilitie current liability cash cash equivalent trade payable bond borrowings trade receivable financial liability inventory income taxis payable contract liability income taxis receivable current liability financial asset subtotal liability directly associate asset hold sale current asset total current liability subtotal noncurrent liability asset hold sale bond borrowing financial liability total current asset net define benefit liability provision contract liability defer tax liability noncurrent asset noncurrent liabilitie property plant equipment total noncurrent liability total liability goodwill intangible asset equity equity attributable owner company investment associate share capital capital surplus financial asset treasury share defer tax asset retain earning component equity noncurrent asset total equity attributable owner company total noncurrent asset noncontrolle interest total equity total asset total liability equity dollar amount report represent translation japanese yen solely reader convenience rate approximate exchange rate december consolidated financial statement note consolidated financial statement refer consolidated financial statement httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report datum section consolidate financial statement otsuka holding subsidiary year end december consolidated statement income consolidate statement change equity billion yen million dollar billion yen equity attributable owner company component equity rev ce su e sale cs ah pa itr ae l c sua rp pi lt ua sl tr se ha ru er sy r ee ra ni ne gd dm e ee n fia nss e u dr f e f ti hmn ra fe oan uic rs g u va hr al e l oa uds te hs e ett rs trc af uo nrr sre e lai ng tc oy n c eh gfl eo sw total total n r ton el rlc eno sgn ts et qo ut ia tl gross profit benefit plan com ip nr ce oh ensive reserve sell general administrative expense balance january research development expense profit year share profit associates comprehensive income income comprehensive income expense purchase treasury share operating profit dividend sharebase payment transaction finance income change ownership interest subsidiary finance cost result loss control nonoperating income expense transfer component equity retain earning profit taxis total transaction owner etc income tax expense balance december profit year balance january change accounting policy attributable restate balance owner company profit year noncontrolle interest comprehensive income comprehensive income earning share yen dollar purchase treasury share basic earning share dividend dilute earning share sharebase payment transaction change ownership interest subsidiary result loss control disposal subsidiary transfer component equity retain earning consolidate statement comprehensive income total transaction owner etc billion yen million dollar balance december profit year million dollar equity attributable owner company component equity comprehensive income noncon com rep mo en ae sn urt es mth ea not sw oi fl l n eo fit n eb de br ee ncl ea fs pf li ae nd profit loss cs ah pa itr ae l c sua rp pi lt ua sl tr se ha ru er sy r ee ra ni ne gd br ee ndm ee e fe n f iia tt n ss pe u lar f e n f cti ohmn mra fe oa p na uic rs r cg eu ova h hr al e el oa ud ens te hs sa e ie vtt r es trc af ru eo nr sr sr ee e la ri ng vtc en oy n c eh gfl eo sw total total nr el rli en sg ts et qo ut ia tl financial asset measure fair value comprehen balance january sive income change accounting policy share comprehensive income associate restate balance subtotal profit year comprehensive income component reclassified profit loss comprehensive income foreign currency translation reserve purchase treasury share cash flow hedge dividend share comprehensive income associate sharebase payment transaction subtotal change ownership interest subsidiary result total comprehensive income loss control comprehensive income disposal subsidiary transfer component equity retain earning attributable total transaction owner etc owner company balance december noncontrolle interest dollar amount report represent translation japanese yen solely reader convenience rate approximate exchange rate december dollar amount report represent translation japanese yen solely reader convenience rate approximate exchange rate december consolidated financial statement note consolidated financial statement refer consolidated financial statement consolidated financial statement note consolidated financial statement refer consolidated financial statement httpswwwotsukacomenirlibraryreporthtml httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report datum section consolidate financial statement group structure overview otsuka holding subsidiary year end december main operating company consolidate statement cash flow billion yen million dollar cash flow operating activity profit taxis depreciation amortization expense impairment loss reversal impairment loss share loss profit associate finance income finance cost nonoperate income expense decrease increase inventory decrease increase trade receivables increase decrease trade payable subtotal interest dividend receive interest pay income taxis pay net cash flow operating activity otsuka pharmaceutical co ltd holistic healthcare company support wholebody health help cure disease promotion everyday health cash flow invest activity keep corporate philosophy company expand operation core business proceed sale property plant equipment pharmaceutical business provide breakthrough treatment patient world nutraceutical business help healthy people healthy payment acquisition property plant equipment otsuka pharmaceutical factory inc original company otsuka group leader iv solution year payment acquisition intangible asset experience intravenous solution business japan proceed sale redemption investment base good partner clinical nutrition management vision company create innovative product meet variety need pharmaceutical medical device oral rehydration solution medical food otc payment acquisition investment drug company expand business globally mainly japan asia payment acquisition subsidiary taiho pharmaceutical co ltd pioneer oral anticancer agent japan half century decrease increase time deposit strive improve human health contribute society enrich smilesthat corporate philosophy taiho pharmaceutical rddriven specialty pharmaceutical company specialize field oncology immunology allergology urology particularly field oncology taiho know lead net cash flow investing activity company japan actively expand global presence consumer healthcare business focus create product help people lead life brim love base customerfirst policy cash flow financing activity otsuka warehouse co ltd contribute people health worldwide field logistic found otsuka warehouse consistently engage logistic pharmaceutical food prod purchase treasury share uct build common distribution platform otsuka group product area pharmaceutical increase decrease current borrowing food beverage daily necessity recent year company grow offer logistic service outside group proceed noncurrent borrowing otsuka chemical co ltd creatively give shape power material customer future repayment noncurrent borrowing material core operation otsuka chemical aim create product bring prosperous living dividend pay society ceaseless technological innovation main business segment hydrazine business inorganic composite material business pharmaceutical intermediate active pharmaceutical ingredient api business company provide product global market area automotive electrical electronic equipment housing healthcare net cash flow financing activity otsuka food co ltd create high valueadde product offer new dietary lifestyle found take company begin people food begin spirit motto otsuka food conduct business increase decrease cash cash equivalent area foods beverage deliciousness safety peace mind well health spirit food cash cash equivalent begin period employee continue develop company deliver product allow customer live healthy life create new dream food effect exchange rate change cash cash equivalent otsuka medical device co ltd aim otsukas medical device business unique introduce new technology cash cash equivalent end period otsuka medical device seeks grow medical device business operate mainly japan china asian country group core business future company strive spur growth dollar amount report represent translation japanese yen solely reader convenience rate approximate exchange rate december bring group medical device experience knowhow integrate new technology introduction new device meet new healthcare need consolidated financial statement note consolidated financial statement refer consolidated financial statement httpswwwotsukacomenirlibraryreporthtml otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report datum section global network corporate informationshareholder information corporate profile company organization otsuka operate december april shareholder meet internal control department company otsuka holdings co ltd board director internal audit department country region nutraceutical business global strategy planning headquarter establish july corporate planning department uk spain sweden czech republic capital billion chairman global business support department germany portugal north president finance accounting department switzerland netherlands europe america head office kandatsukasamachi chiyodaku project office belgium tokyo japan tax department france italy company company tokyo shinagawa grand central tower corporate service department business development department japan headquarters konan minatoku tokyo japan investor relations department telephone administration department company president office canada number consolidate public relation department brazil employees csr promotion department human resources department china indonesia south business description control management relate activity human resource planning department south korea india asia oceania america respect company subsidiary affili taiwan singapore middle east ate active pharmaceutical industry nutraceutical planning department philippine turkey industry consumer product area legal affairs department vietnam pakistan company company statutory auditor statutory auditor office thailand egypt companies board statutory auditor myanmar australia new zealand share december otsuka holding subsidiary affiliate company december number share authorize share number share issue share number shareholder number operation employee principal shareholder shareholder stock distribution number share shareholder share hold treasury security hold ratio share company thousand nomura trust banking co ltd otsuka founders shareholde fund trust account company employee factorie research institutes financial master trust bank japan ltd trust account corporation institution japan trustee services bank ltd trust account breakdown approx otsuka estate co ltd shareholders type otsuka group employee shareholding fund japan japan approx japan japan awa bank ltd outside japan outside japan approx outside japan outside japan japan trustee services bank ltd trust account state street bank west client treaty japan trustee services bank ltd trust account individual overseas corporation otsuka asset co ltd number share hold rounded near thousand history global business expansion company hold share treasury share exclude list shareholding ratio calculate treasury share deduct north america africa western china india south eastern turkey australia egypt europe america europe website information otsuka holding website asia thailand spain brazil czech httpswwwotsukacomen republic visit website otsuka holdings co ltd integrate report otsuka holdings co ltd integrate report significance corporate symbol symbolic representation otsuka group corporate philosophy corporate symbol adopt initial corporate motif represent sky large render grada tion otsuka blue small otsuka red represent focus energy otsuka wellspre tenet offset form poise balance otsuka spell open friendly typeface corporate symbol convey otsuka group energetic commitment human happiness good health